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ABSTRACT
Perkins, Jessica L. BIOFUNCTIONAL COATINGS USING DIRECT-WRITE
FABRICATION TECHNIQUE FOR SURGICAL IMPLANT DEVICES. (Major
Professor: Dr. Salil Desai), North Carolina Agricultural and Technical State University.
Surface modification of biomaterials is of critical value to attain desired
functionality of biomedical devices and implants. Many of the conventional
manufacturing methods used for the fabrication of thin film coatings lack the ability to
precisely dispense biological compounds without compromising its chemical integrity.
This research investigates the use of direct-write inkjet technique for the deposition of
multi-layer coatings of biodegradable polymers. The Direct Write inkjet method provides
selective deposition and patterning capability for depositing multi-material coatings on
biomaterials for a vast array of surgical implant devices (e.g. stents for cardiovascular
applications and orthopedic implants).
In the first phase of the research, an elastomeric polymer, namely polyesterurethane urea (PEUU) was used to encapsulate an anti-proliferation drug paciltaxel
(Taxol). The direct-writing process was employed to coat multiple layers of this
polymeric formulation on a model titanium alloy surface. Characterization

experiments

were conducted to observe the influence of drug dosage and coating thickness on the
release kinetics of the multilayer coatings. Drug release kinetics were characterized using
an ultraviolet-visible spectrum (UV-Vis) spectrophotometer and surface morphology was
assessed using optical microscopy and scanning electron microscopy (SEM).
Biocompatibility tests were conducted to assess the smooth muscle cell inhibition and
platelet adhesion properties of the coatings.

The effects of drug dosage and layer

thickness were evaluated via statistical significance tests. Tunable drug release coatings
can be developed for an intended application by manipulating a given set of input factors.
In the second phase of the research, the direct-write printing process was utilized
to deposit precise layers of multilayer polymeric coatings on magnesium alloy surface.
Biodegradable magnesium alloys provide substitutes for permanent metal implant
materials such as titanium or stainless steel. Polymeric coatings provide a barrier layer
that can retard the corrosion process of the magnesium alloys for vascular and orthopedic
applications. Poly(lactic-co-glycolic acid (PLGA), polycaprolactone (PCL), and PEUU
were chosen based on their varying degradation properties. Immersion studies were
conducted in a simulated body fluid (SBF) to determine the corrosion behaviors of
different sample types using inductively coupled plasma spectroscopy (ICP).
Biocompatability tests such as the lactate dehydrogenase (LDH) assay were conducted to
assess the cytotoxicity levels induced from magnesium ion exposure. A reduction in
magnesium ion content was observed from the polymer-coated samples. Findings also
showed correlation between the release of the magnesium alloy and the health of normal
human bronchial epithelial cells evaluated using the COX-2 gene expression.

This

research establishes a foundation for identifying candidate polymer coatings to control
the corrosion of magnesium alloys.
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CHAPTER 1
INTRODUCTION
1.1 Overview
The design of newer and more effective drug delivery systems have begun to
emerge in the field of biomedical engineering, specifically pertaining to the development
of biodegradable and bioabsorbable implant materials. Developments in metal alloying
and surface modification processes are at the forefront of many research endeavors where
the intent is to develop revolutionary biomaterials. Concurrently, the study of temporal
and spatial release kinetics of pharmaceutical reagents from drug-eluting surgical devices
such as cardiovascular and tracheal stents and orthopedic implants is of growing interest
[1-4]. Surface modifications via different coating techniques, can be applied to various
biomaterials to enhance their biocompatabily and thus enhance their effectiveness in
treating the various post operative effects associated with surgical implant procedures [59].
The use of metallic biomaterials for biomedical applications requires that a
number of conditions be met. The material must be biocompatible and corrosion resistant
so as not to release undesired metal ions into the body [10]. It must posses an adequate
mechanical strength, thus eliminating potential for fracture and must be free of toxic
response within the body or host site [11]. Some commonly known materials used for
fabrication of metallic stents include stainless steel [11], nickel [14], titanium alloys [1011], iron, and magnesium alloys [10-14]. Similarly, silicone and certain polyurethanes
have been used for fabrication of cardiovascular and thoracic devices due to their
1

favorable biocompatible properties [15]. A comparison of the various implant materials
with their respective advantages and disadvantages is provided herein.
1.2 Biomaterials for Implant Manufacturing
The most common stent materials include metallic, polymer, and silicone [15].
Of the metallic group, materials can be further cateragorized into those that are toxic,
non-toxic and bioinert, non-toxic and bioactive, and non-toxic and bioabsorbable [16].
Metallic materials which have already been accepted for use as surgical implant materials
such as stainless steel and titanium are considered as non-toxic, bioinert materials as they
do not release any immediate toxic ions into the body, however materials in this category
may result in the death of surrounding cells or tissues over time [17]. This is depicted in
Figure 1.1. The Wallstents generally used today are manufactured using these non-toxic,
bioinert materials.

Figure 1.1 L. Henchs' catergorization of tissue implant responses
2

The metallic stent (or Wallstent) generally consists of a wire-like, criss-cross,
stainless steel mesh having a tubular shape and offers the mechanical strength necessary
to prevent restenosis, or collapse of the arterial wall, after angioplasty [18]. The diameter
of the metallic stents’ outerwall is also thinner, allowing for a larger inner diameter and
increased blood flow through the arteries. Another important advantage is the lack of
migration that occurs once the device has been placed. In contrast, the silicone design
has a rather narrow inner diameter due to its thicker outer wall and issues with migration
and dislodging have been observed [19].
Disadvantages of the metallic, mesh-like design is that it is generally permanent
due to partial or full integration into the airway or arterial wall, making the removal
process difficult whereas the silicon stent is easily removable and may be exchanged
frequently [19]. Environmental factors that inhibit the effectiveness of metallic tubular
supports include in-stent granulation tissue formation, inflammatory disease, smooth
muscle cell migration, stent thrombogenicity, and neointimal hyperplasia [20].

The

presence of these factors are more prominent when bioinert materials are employed.
Thus, they are identified as a foreign body object within the physiological environment
and become encapsulated within a fibrous mesh. Subsequently, this can bring about
increased external forces causing the tubular mesh to collapse, also referred to as
restinosis [21]. With the transition from bioinert to biodegradable and bioabsorbable,
more and more research scientist are beginning to focus on magnesium and its alloys as
ideal candidates for surgical implant materials.

3

Magnesium is the fourth most abundant mineral found in the body, thus it is
necessary in order for the body to remain in good health [22]. What makes magnesium
such the ideal candidate for surgical implant materials is its ability to perform an intended
function, degrade and become absorbed by the body without leaving any trace or toxic
effects [23]. In a study conducted on atherosclerosis risk in communities, the authors
suggests that there exists a connection between patients who suffer from cardiovascular
disease and magnesium deficiency [24]. Thus magnesium-based, bioabsorbable stents
are of increasing interest for patients suffering from heart disease.

Figure 1.2 Depiction of matching Mg degradation and bone growth processes
Magnesium is also an ideal candidate for orthopedic implant devices for bone
growth and fracture repair due to it similar mechanical properties to bone. The material
offers such advantages as more physiological and less invasive repairs, possibility of
tissue growth, temporary support during tissue recovery, and gradual dissolution by the
physiological environment after it has performed its intended purpose.

However

magnesium alone tends to degrade at an accelerated pace in saline environments thus not
4

allowing enough time for the device to perform its intended purpose. A depiction of this
concept is shown in Figure 1.2. Recent research being conducted at the Engineering
Research Center for Revolutionizing Metallic Biomaterials has applied various metal
alloying and surface modification techniques to control the corrosion of magnesium.
In addition to the use of magnesium alloys for implant and stent manufacturing,
these materials can be coupled with a multi-functioning polymeric coating that can
extend magnesium corrosion rates long enough for the stent to serve its purpose as well
as administer any necessary therapeutic drugs. These coatings also add several other
benefits, which are described further in the upcoming sections.
1.3 Polymers for Stent Coating
Over the past decade researchers have examined a number of ways in which
pharmaceuticals can be transported via stent-mediated drug delivery methods. Some of
the methods found in literature range from synthetic and organic biodegradable polymers
to non-degradable polymers. The perusal of non-degradable polymers for biomedical
uses led to less than satisfactory results for stent coating applications [25]. It is believed
that the presence of the foreign body causes inflation and infection at the implant site,
thus magnifying an already complex situation. Biodegradable polymers were studied for
stent coating as they offered a decrease in the number of surgical procedures required for
device removal and a significant reduction in the number of restinosis cases [21].
Contrasting studies from other cases, however, claim that the use of polymers in general
may be incompatible with the blood thus increasing the risk of thrombosis. This

5

conclusion caused experts to investigate other alternatives for achieving localized drug
delivery using stents.
The uses of degradable polymers as a mechanism for drug delivery was revisited
(after considering a number of other coating materials and their associated effects).
Materials such as Sirolimus [26,28], Paclitaxel (Taxol) [25-28], and Phosphorylcholine
(PC) have been used to directly coat bare metal stents (BMS). In some cases these
materials were used as mechanisms for the entrapment of other medicines within
themselves. The use of PC has been used as a binding mechanism to carry drugs to
treatment sites [29].
The employment of non-polymeric coatings showed great promise in the fact that
in most cases 100% efficacy was observed in terms of the intended amount of drug
required for healing [25-28]. There was, however, an essential limitation of this method.
The rate at which these substances were released ranged from around 60% to 80% in the
first two or three days with subsequent elution of the remaining drugs releasing over the
next 28 to 35 days [30]. This phenomenon is commonly called as a burst effect or initial
burst period.

However, a procedure for mediated delivery of pharmaceuticals over

extended periods of time was desired.
1.4 The Model Stent
The model stent design would be one that contains select properties of both the
metallic and biopolymer tubular support systems.

The selected material for stent

manufacturing would be bioabsorbale, having the ability to dissolve into the surrounding
tissue without toxic effect.

The metallic wire mesh covered with a biodegradable
6

polymer would offer the mechanical strength required to maintain an open airway or
blood vessel and allow for a higher blood flow rate (cardiovascular). A thin biopolymer
coating would not only add a second dimension to the stenting device as a protective
barrier to increase the time span in which the stent remains operative, but could also serve
as a drug carrying device.
In addition to the increased functionality of tubular support structures following
coating and/or polymeric surface treatments, more case specific advantages are realized.
For example, late-stage lung cancer patients facing acute tracheal restenosis due to the
rapid in-growth of a malignant tumor would require rapid, site-specific, chemotherapeutic
sessions over an extended period of time. Local delivery of a drug to the cancerous site
via a polymer-coated stent can reduce the exposure of toxins to the body, thus ridding the
impaired site of only the unwanted cells. Also, the polymer matrix grants sustained
treatment over time, eliminating the need for repetitive surgical procedures and their
associated risk as well as substantial medical costs [31]. Literature suggests that a
biodegradable polymer matrix containing drugs such as Palcitaxel and Sirolimus, which
inhibit the migration and proliferation of smooth muscle cells, could be used as a
mechanism for treatment of neointimal hyperplasia [32].
The study of sustained drug release has important implications in the biomedical
arena. Research in the field of tissue engineering has integrated the theory of sustained
release to deliver Nerve Growth Factors (NGF) encapsulated in polycaprolactone (PCL)
to preserve bioactivity for the construction of biofunctional tissue scaffolds [33].
Sustained release of NGF was achieved for three months [33]. Research scientists at the
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Wake Forest Institute of Regenerative Medicine have achieved sustained release of
oxygen ions to facilitate cell survivability during the brief period between the
implantation of tissue engineered organs and the establishment of neovascularization
where eventual tissue and cell necrosis may occur [34].
The above-mentioned applications have demonstrated the success of achieving
prolonged periods of release for biomaterials having a single polymer matrix layer in
which the resulting release profiles are a function of degradation properties of the
biopolymer (carrier) and the rheological properties of the eluting substance (drug).
Careful consideration of controllable factors such as polymer type, layer thickness,
drug/agent use, and spatial distribution can result in distinctly, defined temporal release
patterns.
1.5 Coating Technologies
A number of technologies have been applied for the deposition of polymer thin
films onto metallic substrates, each having their own advantages and disadvantages.
Techniques such as sputter deposition use a physical vapor deposition (PVD) process,
which involves the bombardment of the targeted coating material followed by the
evaporation and transportation of the evaporated material to a particular substrate.
Sputtering offers great surface adhesion properties, a variety of grain sizes and
orientations, and easy control of coating thicknesses. This process usually takes place
inside a vacuum with line of site deposition making it difficult to coat substrates, such as
stents, designed with undercuts and special features [35]. An important limitation with
this process is the restricted amount of control over the vaporized coating material as
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they are transported to the substrate resulting in wasted material. Lastly, some of the
targeting coat materials are susceptible to premature degradation due to the ionic
material used during the bombarding process [35].
The electro-spinning and -spraying techniques both use electricity, or an applied
voltage as the source for carrying out deposition processes.

The electro-spinning

requires a high voltage to be applied to the coating solution, which has been previously
loaded into a spinneret [39]. Once a voltage is applied to the spinneret it is subjected to
a whipping motion and a continuous jet is ejected. This continuous jet is collected on an
oppositely charged substrate.

This process is more appropriate where a mesh-like

coating with high porosity is desired.
Dissimilarly, the continuous jet emitted from a stationary metallic or glass
capillary during the electro-spraying process is subject to electrostatic forces, which
result in a cloud of positively charged particles. The particles are then deposited onto an
oppositely charged substrate [36-39]. Both the electro-spinning and spraying processes
are able to deposit highly porous films using a variety of different materials. They each
have displayed high tensile strength and tunable mechanical and degradation properties.
Neither of the two methods requires the use of heat, making them ideal for the use of
biomaterials. However, they do result in high amount of wasted materials and lack
precision abilities for patterning.
The dip coating and spin coating deposition processes are less complex yet they
provide a more uniform coatings. The dip coating process is good for coating more
complex structures and has a high deposition and processing rate [40]. This process,
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however, does not provide variance as far as spatial control and is also inflexible in terms
of switching out coating materials. The spin coating process is also an extremely fast
paced process, however it is limited to possessing only one substrate at a time. It also
lacks in the areas of material efficiency (only two to five percent of deposited material
left on the substrate), repeatability, and thin film deformity. Lastly, this technique cannot
accommodate the need for coating two or three-dimensional structures [41].
A newer and more complex technique is one known as Layer-by-Layer selfassembly [42-44]. This is a process in which thin films are deposited by alternating
layers of positively and negatively charged coating materials incorporating a wash step
in between. This technique might offer a high degree of controlled thickness (atomic
thickness), ability to coat a variety of materials such as biomaterials, the coating of
difficult geometries. In contrast, this method also has its limitations. This process
produces excess film build up, hence the need for a washing process in between layers
and further study is required regarding the reaction between the charges coating
materials and blood containing ions and polyelectrolyte (proteins). This process is
usually performed in combination with another deposition method (e.g. dip coating,
spraying) and so one might also notice some similar advantages and limitations to those
already discussed [42-44].
As implicated, all of the processes mentioned allow for the manipulation of
coating thickness and surface morphology to some degree, therefore providing some
control over the fabrication procedure. Each process is capable of depositing varying
types of materials such as metallics, polymers, and other organic materials for a range of
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different applications. It has also been noted that the achievable film (or layer) depth for
this set of deposition processes range from atomic to nano thicknesses. Though the
aforementioned techniques all possess some desired features of a deposition process to
be utilized for the manufacture of biodegradable coatings, they all commonly lack the
ability to deposit precise and localized coatings of three-dimensional complex structures.
Inkjet printing techniques have been studied and applied as a method of drug
delivery. The technique produces droplets of ink through a jetting process via a small
aperture, such as a nozzle or glass tip, onto a media. Inkjet printing can be achieved
using either of two methods [45]. The first, being continuous inkjet printing process.
Continuous inkjet printing yields a continuous stream of ink that is broken down into
droplets of uniform size and spacing. An electric charge is selectively applied to the
droplets passing through an electric field and are retained and recycled into the system,
whereas the droplets free of the electric charge are deposited onto the media to form and
image [45].
1.6 Drop-on-Demand Inkjet Printing Technologies
More appropriately used is Drop-on-Demand (DOD) Inkjet printing process. This
method produces droplets of ink as they are needed as opposed to a continuous stream.
The need for electrical charge in a magnetic field as well as the complex and unreliable
recirculation systems required in the Continuous Inkjet System are eliminated, making
this system more desirable for coating of complex structures (picoJet technology).
Jetting is observed through one of the following approaches: thermal, piezoelectric,
electrostatic, and acoustic. The two most popular are thermal and piezoelectric.
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The piezoelectric method is named after the deformation ability of the
piezoceramic material used in the inkjet device. In it there are four different methods in
which the piezoceramic material can function. The four methods include squeeze, bend,
push, and shear. Squeeze mode ink jet can be designed with a thin tube of piezoceramic
surrounding a glass nozzle. In a typical bend mode design, the piezoceramic plates are
bonded to a diaphragm forming an array of bilaminar electromechanical transducers. In a
push mode design as the piezoelectric rods expand; they push against the ink to eject the
droplets. The shear mode design deforms the piezoelectric against ink to eject the
droplets. In this case the piezo becomes an active wall in the ink chamber. Interaction
between ink and piezoceramic is one of the key parameters of a shear mode print head
design. For the purposes of this research, the piezoelectric approach would be more
suitable as the thermal approach is expected to alter the properties of the biological agents
used [45-48].
1.7 Research Objectives
This dissertation focuses on the application of a novel surface modification
technique for developing functional coatings for metallic biomaterials. Inkjet printing
offers several advantages such as the capability to produce coatings on extremely
complex structures, deposition onto the outer surfaces only, and flexibility to change
coating design and materials. This technique also allows for the adjustment of coating
thickness with the objective of obtaining desired release patterns.
Direct write inkjet printing techniques were used develop multilayer coatings
laced with a pharmaceutical reagent for the purpose of studying controlled release
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kinetics. The coatings types were varied in concentration and thickness to determine how
manipulating the two would affect the drug release profile.

The reagent chosen,

Paclitaxel, has been proven to inhibit accelerated cell proliferation in cancerous
environments, thus biological testing was conducted to relate the drug release profiles to
cell inhibition. Hemocompatability test were also conducted to relate drug release to
blood coagulation on the functionalized surfaces.
In a second study, the direct write techniques were used to develop polymer
coatings that would aid in corrosion retardation of magnesium alloys for orthopedic and
vascular applications.

It was believed that by manipulating droplet sizes and pitch

distance as well as polymer type and thickness, that desirable corrosion rates based upon
a given application could be obtained. Cell viability and surface interaction of the
magnesium alloy and various coating types were also explored. The main objectives of
this research are plainly stated:
1. Develop controlled release coatings using direct write inkjet technologies.
2. Study the relationship of drug release profiles to cell growth inhibition and
hemocompatability of coated and uncoated metallic surfaces.
3. Develop polymeric coatings for corrosion retardation of magnesium alloys using
direct write inject technologies.
4. Assess the corrosion behavior magnesium alloys (AZ31) with modified coating
surfaces.
5. Assess the cell viability and biocompatibility of Normal Human Bronchial
Epithelial cell after controlled magnesium exposure.
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CHAPTER 2
LITERATURE REVIEW
2.1 Surface Modification and Functionalization
The surface modification and functionalization of metallic materials is being
proven to be an essential step in making materials more biologically compatible with the
human physiological environment. Its relevance has become intensely important in the
medical field as different materials are explored for their use and performance in the
development of transplant and surgical devices. As the need for more biocompatible
surfaces arise, research scientist have began to focus their efforts on ways to enhance the
physical, chemical, and biological properties of surfaces which they do not originally
possess. The uses for multi-functional surfaces can increase the life span of implant
devices and reduce the need for surgical procedures.
A number of processes that are employed for use in surface modification
procedures are explained.

These procedures are necessary to inhibit the profound

environmental reactions to surfaces causing wear, corrosion, and fatigue. Biochemical
modification through physical vapor deposition [49], self-assembly modification [50],
and radio frequency glow discharge [51] are a few of the most popular techniques used.
Ferretti et al. argued that the advancement of self-assembled monolayers (SAM)
could be sufficiently used for the development of monomolecular layered bionsensor
devices [52].

By fabricating layers of biomolecular agents, which could simulate

reactions with natural bodies, these devices could eventually be used to facilitate natural
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functions [52].

An in depth review of processes to be used for this application

accompanied by the advantages and disadvantages of each were described.
With an effort to improve thromboresistance, or blood compatibility, of a titanium
alloy (TiAl6V4) for ventricular devices, recent research efforts have been focused on
possible chemical surface modification techniques [53]. A silane-coupling agent (APS)
was used to covalently attach a phospholipid polymer (PMA) through radio frequency
glow discharge. The coupling agent was used to tightly bond together the PMA to the
titanium alloy, where typically a reaction would not occur. PMA was chosen due to its
excellent ability to reduce platelet adhesion and coagulation of the blood at the medical
implant site [53]. Modification of the Ti alloy surface added functionalization to the
surface, which would have otherwise been biologically incompatible. Characterization
by X-ray photoelectron spectroscopy showed success of the surface modification
procedures and thereby a reduction in adsorption of ovine sheep blood platelets [53].
2.2 Controlled Degradation of Magnesium for Surgical Implant Materials
Towards the study of Magnesium (Mg) and its alloys for its application in implant
materials, it has been noted that the material exhibits excellent biocompatible properties
(similar to that of the bone structure) [54]. Its high tensile and yield strength as well as
its density makes it an ideal material for biomedical implant devices [54]. However, its
position on the galvanic chart is an undeniable indication of its susceptibility to corrosion
in certain environments. Several studies have been conducted in efforts to control the
corrosion rates of magnesium-based implants long enough for the device to carry out its
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intended purpose.

Two of the major mechanisms found in literature include metal

alloying and surface modification for controlled degradation of magnesium.
2.2.1 Alloying for Controlled Degradation of Magnesium
In a recent study, Gu et.al. studied the in vitro corrosion and biocompatibility of
binary magnesium alloys. Nine binary magnesium alloys containing 1% weight, X, of a
proposed alloying component (X=Al, Ag, In, Mn, Si, Sn, Y, Zn, Zr) was tested for their
potential use as biomedical alloying materials [55]. Each of the proposed materials was
subjected to preliminary testing to characterize its microstructural and tensile properties.
Electrochemical and immersion tests were conducted to understand corrosion potential of
each material.

Finally, cytotoxicity and hemocompatibility test were conducted to

determine the suitability of the materials for more specific biomedical applications (e.g.
bone and blood vessel related cellular responses). Gu et. al were able to conclude that
Mg-Al showed positive response for nearly all of testing [55].
Aluminum as a potential magnesium-alloying candidate showed improved
strength of the material, reduced corrosion, acceptable cell viability and toxicity on
fibroblast, osteoblast and blood vessel cells. However, other recent studies have proven
aluminum to have neurotoxicant effects which have been associated with such
neurological disorders as dementia, senile dementia, and Alzhiemer disease. In the same
study zinc, as major magnesium alloying component, also showed similar and favorable
characteristics as aluminum [55].
In another study conducted at the Laboratory of Metal Physics and Technology,
scientist proposed two new Mg-Y-Zn alloys (ZW21 and WZ21) for use as implant
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materials for blood vessel repair (Hanzi et al, 2010). The study focused on in vitro and in
vivo electrochemical and biological responses through electrical impedance spectroscopy
and standard immersion testing [56]. New alloys were compared to the first generation
ZQ30 (Mg-Zn alloy) and a reference alloy, WE43 (Mg-Y-RE alloy) to characterize grain
structure, corrosion potential, and degradation performance [56]. This reference alloy has
been used in clinical trial settings as a stent was developed from this material and inserted
into the aorta of a newborn patient. Upon characterization of the proposed alloys, the
authors conducted animal testing in which sample disks of the WZ21 alloy (chosen
because of its more favorable mechanical performance) were implanted into two
Gottingen minipigs. The samples and surrounding tissues were extracted after 27 and 91
days and results proved that there was a significant reduction in foreign body reaction
activity after more extended implant periods [56].
Many efforts have been made to develop magnesium alloy specifically for bone
regeneration and repair. Li et al. propose a binary Mg-Ca alloy for use as biodegradable
materials with the bone structure [57]. In this study Mg-Ca alloys of various calcium
percentages (Mg-1Ca, Mg-2Ca, Mg-3Ca) were tested to determine structural and
mechanical advantages to bone repair and its potential environmental behaviors.
Immersion tests proved that the Mg-1Ca samples were protected from increasing
corrosion rates due a protective layer formed on its surface from the electrolyte solution.
The findings of the preliminary mechanical and immersion tests led the authors to
select Mg-1Ca to conduct further cytocompatibility and animal testing [57]. Mg-1Ca
pins were manufactured and implanted into the left femoral shaft of 18 New Zealand
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rabbits. The pins were removed after one, two, and three months and characterized by
weight and degradation. Results showed that the pin had completely dissolved at three
months post operation and that newly formed bone was detected using radiographic
examination. However, the issue of premature degradation still remains and further effort
must be made to synchronize rate of degradation with the rate of bone formation [57].
2.2.2 Surface Modification for Controlled Degradation of Mg Alloys
The research group at the Tsinghua University in Beijing, China reports that the
appropriate application of surface modification techniques can be employed to increase
corrosion resistance of Mg and Mg alloys, thus making this material one that could be
used for bone replacement as well as a delivery mechanism to benefit human metabolism
[58]. In addition, Gao and his research group used the heat-self-assembled monolayer
(HSAM) technique to modify the surface of 4N-Mg biomaterials. This group conducted
in vivo studies in which the treated and untreated magnesium materials were implanted
into the thighbone of white rabbits to induce bone growth. They found that the modified
surfaces were beneficial in reducing the rate of corrosion and that corroded magnesium
content in the blood remained within a normal range [50].
2.3 Drug Delivery
Drug delivery is the idea of administering pharmaceuticals to patients needing
medical treatment in specified dosages. There are several methods in which drugs have
been delivered such as orally (through the mouth), topical (through the skin),
transmucosal (through the nose), inhalation, and injection. These methods encompass the
ability to delivery various types of drugs and biological compounds as vaccines, proteins,
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and other therapeutic systems. Over the past few decades localized, or targeted delivery
has become a favorable drug delivery method in that it limits toxicity to the human body
by only treating the infected site [59]. This type of drug delivery system (DDS) also
increases bioavailability of drugs [59].
An earlier inception of localized drug delivery involved the use of drug-eluting
nanoparticles for the treatment of restenosis.

Insertion of the nanoparticles was

administered through a catheter apparatus. Researchers investigated the effect of two
different agents, dexamethasone and an aminochromone antriproliferative agent, on
restenois in a rat carotid and porcine coronary model [60-61]. The results showed
promising signs towards the inhibition of restenosis.

Furthermore, herparin anti-

coagulation drugs were incorporated into the nanoparticles for testing in pig coronary
arteries for the reduction of platelet deposits and desirable results were achieved [62].
The findings proved to be even more promising as it was observed that the nanosized
particles could be dissolved into the arterial walls without damage to the treated site.
Another study integrated the use of a rat model to deliver the growth factors IGF-I
and TGF-B1 from a biodegradable matrix previously coated onto a titanium plate to treat
the instability of long bone fractures [63]. Biomechanical testing was incorporated to
determine if the growth factors effectively enhanced the healing process. The results
showed that complete healing of the fracture had not taken place 42 day after surgical
implantation, however biomechanical strength was restored with two days of surgery.
The results obtained from the coated group were significant compared to the controlled
(uncoated) group [63].
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2.4 Temporal Release
Recent studies have introduced complex biphasic/triphasic and tetra-layered
systems when a series of treatments are required over an extended period of time.
Careful consideration of controllable factors such as polymer type, layer thickness,
drug/agent use, and spatial distribution can result in distinctly, defined temporal release
patterns. Okuda et al. were able to develop tetra-layered nanofibrous meshes for in vivo
testing to obtain timed-programmed release patterns [64]. Timed release was achieved
by setting the parameters for fiber diameter, mesh layer thickness, polymer concentration,
and the use of a barrier mesh with controlled thickness. Each layer was fabricated using
electrospinning technique and a polymer solution doped with two different types of dyes
to simulate the release of pharmaceutical compounds [64].
Li et al. present a method for achieving well-defined spatial and temporal release
profiles for a drug-eluting MEMS device loaded with various compounds to be released
sequentially [65]. Fabrication of the MEMS devices requires the use of an etching
process and a silicon substrate to etch strategically placed, well containing reagents. The
wells were covered with a gold membrane expected to corrode based on electrochemical
principles [65]. In the article titled “Modeling and Simulation of drug release from
Multi-layered Biodegradable Polymer Microstructure in Three Dimensions,” cellular
automa 3D modeling software was used to describe the dynamic behavior of multilayered polymer structures with uniform and nonuniform chambers [66]. The article
presents a novel method for modeling drug delivery microstructures. Polyanhydride was
employed to create structures with various micro chamber shapes capable of
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encapsulating a variety of different agents. The structures were stacked using glue to
create a single multi-layered structure. The outer boundary was expected to degrade over
time to promote sustained release [66]. A Monte Carlo based two dimensional model
developed in the late 90’s has been able to predict prolonged release rates of encapsulated
drugs; however, the authors determined that a three dimensional model was needed for
more valid characterization. The 3-D model was compared to that of the 2-D model
using the same suggested parameters and findings were analogous. The authors then
optimized the parameters and formulated a hypothesis that would test the models
performance on two different types of multi-layered systems [66]. Results showed that
cellular automa could be used as an accurate predicting model to characterize release
behaviors.
2.5 Current Coating Technologies
The coating technique proposed for surface modification and/or functionalization
of metallic surfaces is one that is unique to a specific application. In some cases it may
be necessary to perform two or more different methods successively to achieve the
desired results. This section presents a few of the widely used methods for coating
metallic surfaces along with their advantages and disadvantages.

Desirable

characteristics for application of coating biological agents are also highlighted.
2.5.1 Electrospinning
The electrospinning process uses an applied voltage as its main source. The
equipment setup can either be one that is vertically or horizontally mounted [39].
Electrospinning requires that the coating solution be loaded into a spinneret apparatus
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where a high voltage is applied. Following the application of the voltage, the nozzle
portion of the spinneret is subject to a whipping motion and a continuous jet is ejected
(Figure 2.1). The collector, or substrate, having an opposite charge is placed opposite of
the nozzle capillary where the coating material is deposited and the thin film is formed
[39].

Figure 2.1 Schematic of the electrospinning process [43]
The process parameters having a profound effect on such measures as fiber
diameter, pore size, film porosity, and film thickness include: electric potential; flow rate;
concentration of the coating material; target motion; and the distance between the
spinneret and the target substrate.
The process offers a number of advantages making it an ideal process for
depositing bio thin films. For instance, the process provides a high surface-to-volume
ratio, good tensile strength and the use of a wide variety of coating materials. It does not
involve the use of heat and so it is ideal for the deposition of biological agents. Also,
tunable mechanical and degradations properties can be achieved. Limitations of this
process are subjective depending on thin film application [39].
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2.5.2 Dip-Coating
The dip coating process can accommodate flat or cylindrical substrates. The
substrate is submerged into the coating solution. It is during this step that deposition
takes place. Withdrawal occurs at a constant speed and this is what determines the thin
film thickness (Figure 2.2). For instance, the faster the withdrawal speed, the thicker the
thin film layer [40]. Any excess liquid is drained from the surface and the solvent begins
to evaporate. This process is repeated for each additional layer that is desired.

Figure 2.2 Schematic of dip-coating process
The goal throughout the deposition process is to obtain a uniform coating
thickness with desirable film thickness and surface characteristics tailored to a specific
application. The tunable process parameters include the withdrawal speed, gravitational
acceleration, rate of solvent evaporation, number of dipping cycles, dwell time, and fluid
properties.
Like many other thin film fabrication techniques, this process also has its
advantages and disadvantages. For instance, dip coating is more suitable for coating
substrates with complex shapes and undercuts. The production rate is extremely high as
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multiple collectors can be processed at a single time. Contrarily, coatings cannot be
spatially controlled and the changeover time is extended making the process one that is
inflexible for coating layers of various materials.
2.5.3 Layer-by-Layer (Self-Assembly)
A newer and more controllable thin film fabrication technique is layer-by-layer
deposition. This process involves the growth of thin films by depositing alternating
layers of positively and negatively charged layers with a washing procedure in between.
The bonding of the two charged layers is termed as a bilayer. Deposition of each layer is
usually performed by a more simplified deposition technique (e.g. dip coat or spray) [43].
Measures of the film thickness, roughness, and porosity are usually a function of pH,
ionic strength, and polyelectrolyte concentration (Figure 2.3).
Due to the compositions of ionic bonding layers, one might be able to insinuate
that a great advantage of this coating process is the fine control of drug loading and layer
thickness. With this process atomic monolayers of the coating materials are achievable.
Concurrently, a wide variety of coating materials from biological agents to metallics can
be deposited onto complex geometries.

This process does, however, pose several

limitations in that an extra washing step required is due to excess film build up, also
implicating a high volume of wasted material. In addition, it was mentioned that further
studies must be conducted to study the reaction between the charged coating materials
and blood containing ions and polyelectrolytes in proteins [44].
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Figure 2.3 Schematic of layer-by-layer assembly process [45]
2.5.4 Sputter Deposition
Sputter deposition is a physical vapor deposition process in which a discharge of
sputter gas, usually argon, is directed at a target containing the coating material [35]. The
reaction between the gas (or ions) and the target materials brings about a sputtering
reaction, which initiates the transport of atoms from the target to the substrate (Figure
2.4). The sputtered atoms are condensed on the substrate resulting in a thin film coating.
A great advantage to the application of depositing biomaterials is that this process
does not require the use of heat, which could possibly alter the biological properties of
the substrate. In contrast, the bombardment of the ions may introduce impurities to the
collector, or substrate, thus resulting in its premature degradation. Use of this technique
also provides the enhancement of adhesion to surface and easy control of film thickness.
Nevertheless, the transportation of atoms is non-directional so consequently they may be
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deposited on any surface within the vacuum chamber [35]. This can result is elevated
amounts of waste.

Figure 2.4 Schematic of electron sputtering process [46]
2.5.5 Spin Coating
Spin coating techniques have been used to apply thin films with less than 10
nanometer thicknesses. The procedure involves discharge of the bulk coating material
from a nozzle onto the substrate, previously loaded onto a rotational tool. The loaded
substrate containing the coating material is then subjected to high centrifugal forces
causing the fluid to be directed to its edges [41]. During the rotation process the solvent
begins to evaporate resulting in a thin film coating (Figure 2.5).
Spinning is a rapid process and the variables required to adjust the coating
thickness is limited [41]. The primary process parameters include spin speed, viscosity
of the coating solution, and spin time. The use of this process, however, is limited in that
it can only coat flat surfaces one substrate at a time resulting in a low production rate.
Literature also suggests that after completion of deposition only two to five percent of the
loaded coating solution remains on the substrate. It seems, however, that the greatest
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drawback is low repeatability and difficulty to maintain a uniform film despite
consistency of the processing parameters. This issue results in a number of unusual
deformities that may be undesirable for certain applications.

Figure 2.5 Schematic of spin coating process [47]
2.5.6 Electro-Spraying
Electro-spraying deposition is another apparatus that employs the use of
electricity to coat thin films. The electrostatic forces applied to a continuous stream of
the coating materials aids in the deposition process [36]. During this process, the liquid
at the capillary becomes unstable to the point were it can no longer hold the charge and
disperses into a cloud of highly charged particles (Figure 2.6).
The process parameters having a profound effect on such output measures as film
thickness, morphology, uniformity, and porosity include the following: growth rate,
solvent evaporation rate, concentration, spray temperature, and deposition time. This
process, however, is extremely sensitive to the physical properties of the fluid and is
limited to the use of solutions with low conductivity. Advantages of the electro-spraying
techniques are that it does not cause damage to the deposited biomaterials. Also, high
definition efficiency can be achieved (about 80%) [36-38].
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Figure 2.6 Schematic of electro-spraying process [48]
2.5.7 Coating Processes for Drug-Eluting Stents
Careful consideration is required when determining the appropriate technique to
be used for the fabrication of biological materials and thin films.

Processing that

involves the altering of biological agents and/or their characteristics such as those that
require the excessive use of heat or elevated pH or acidity levels should be avoided.
When coating surfaces of drug eluting stents the drug containing solution should not be
subjected to processes in which excessive heat or inappropriate pH levels would alter the
performance characteristics of the device in vivo.
Researchers at the National Cardiovascular Center Research Institute developed a
multi-drug-eluting stent with micropores to reduce neointimal hyperplasia and minimize
coagulation of blood platelets at the implant site. The dip coat method was used to
deposit a layer of segmented polyurethane (SPU) onto the inner and outer surfaces of a
Palmaz-Schatz stent manufactured by Johnson and Johnson. A excimer laser apparatus
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was used for micropore fabrication and then again to ensure immobilization of the
heparin coating (inner surface) and FK506 immunosuppressant (outer surface) coatings
that were applied [67].
The coating method that was chosen aided in the prevention of plaque build-up
within the struts of the stent, limiting thromboresistance. The technique resolved the
issue of the undesired structure of the luminal surface resulting in the flat surface needed
for experimental success. The irradiation process used for the immobilization process did
not pose any threat to the functionality of the chosen biological agents. In vivo results
showed that the multi-drug coating did reduce neointimal hyperplasia and thrombosis
[67].
Another study claims the development of a novel biodegradable polymeric
matrix-coated cardiovascular stent for controlled drug delivery through the use of an
individualized drug-eluting stent system to abrogate restenosis (ISAR). The authors here
use a modified air suspension coating technique in which the wire mesh-like stent is
suspended vertically between two hooks that are linked to the coating device. The
coating solution reaches the 0.2mm diameter nozzle while under gravitational influence
and is eventually ejected from the capillary and subjected to a pressure drop atomizing
the liquid into fine droplets. Multiple layers (4) of coating solutions were collected on
the rotating stent [68].
It was observed that the coated stent in this study maintained a standard uniform
coating free from impurities following the successful optimization of parameters such as
gas pressure, flow rate of the solution, and distance between the nozzle and stent.
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Mechanical properties of the coating were also tested at stent site and subjected to the
maximum permissible stress. The results of SEM imaging and the findings of film
stability confirmed complete adhesion of the film. Finally, processing of the coating
materials through the use of gravitational forces and air pressure did not result in the
alteration of either the biological components or substrate [68].
In a research study published by the American Heart Association, an on-site
coating apparatus is used to apply pharmaceuticals for the direct use of drug eluting
stents. The process maintains sterility throughout the duration of the application period.
The drug-eluting stent fabrication design allows for individual doses of a specified drug
in a drug reservoir to be connected to a disposable stent cartridge under sterile conditions.
The stent, mounted onto a balloon catheter is positioned inside of the disposable cartridge
and is ultimately motioned horizontally through a ring containing three nozzles. Upon
application of the coating solution via spray coating mechanism, the stent is dried by
sterilized air pressure and is removed for immediate use [69].
A process such as this was necessary to ensure that materials are free from
contamination. Given that the deposited solutions are bare drugs, appropriate precautions
were taken to ensure that the functionality of the drugs is not disturbed. The coated drugeluting stents were immediately used for inhibition of neointima, or accelerated growth of
unwanted cells.
The recent application of this method was carried out for the fabrication
rapamycin-eluting stents [70]. The systematic release of probucal was also reviewed.
This non-polymeric coating technique was sought as a method to deliver drugs in a way
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that does not introduce unnecessary cardiac events into the healing process. To assess the
effectiveness and safety of these newly developed stent coating techniques, rapamycin
and polymer coated stents as well as a control (bare metal stents) were placed in a porcine
model where the effects of fibrin deposition was closely monitored [70]. Results showed
that fibrin deposition was significantly higher in biodegradable polymer-based stents.
2.6 Uses of Ink-jet Printing Technologies
The use of inkjet printing technologies for the deposition of biological materials is
becoming more relevant for applications in biomanufacturing. The non-contact printing
technique has been used for the fabrication of solid and multilayered microspheres,
deposition of biopolymeric materials for uses in tissue engineering, and bioMEMS and
microfluidic applications [71]. Inkjet printing, also referred to as a direct-write process,
offers several advantages in the deposition of biological agents such and DNA, proteins,
and growth factors for tissue engineering applications. A primary advantage is that
during the deposition process, the coating materials are not subjected to elevated
temperatures that could potentially alter both the biological and fluidic properties [71].
Other advantages of this technique are its ability to produce highly uniform microdroplets
as well as a precise deposition tool to fabricate very small and complex structures. A full
list of advantages can be found in Table 2.1.
In an article released from MicroFab Technologies, Cooley et al. presents inkjet
printing as a suitable technique for manufacturing biological micro-electromechanical
systems (bioMEMS) [72]. The current technique for the fabrication of these devices
consists of photolithographic process that requires exposure and/or etching of
31

biomaterials to create a pattern or coating. The etching process lacks control, which
affects the thickness of the applied coatings. The direct-write technique is a safe
procedure that does not introduce harmful chemicals. It is a three-dimensional printing
process that allows for easy manipulation and achievement of uniform coating
thicknesses [72].
Table 2.1 Advantages of Direct-write inkjet technique
Advantages of Direct-Write Inkjet Printing
1.
2.
3.
4.
5.
6.
7.
8.

Non-contact, reduced cross-contamination of substrates
No thermal influence
Precise and accurate printing
Prints a variety of materials and biomaterials on a variety of substrates
Fast Process
Low start-up cost
Data-driven and safe process
No chemical waste

The inkjet printing process may be achieved using one of three different methods:
thermal, continuous, or piezoelectric drop-on-demand. For reasons mentioned above, the
use of the first two methods have been discouraged for printing biological agents onto
small, complicated structures.
In a recent study, also conducted in conjunction with MicroFab Technologies,
Inc., a standard JetLab system was used to fabricate PLGA microspheres, which had been
loaded with paclitaxel drug and thin films of fenofibrate for stent coating applications.
The materials selected were required to meet four specific criteria: 1) the ability of the
material to degrade after performing its drug delivery function 2) the ability to sustain
cell viability 3) the ability to sustain proper cell functioning and 4) the ability to be jetted
at high concentrations for extended time periods [73].
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Drug release and bioactivity of the drug containing microspheres and thin films
were observed using UV spectroscopy and MTT assay respectively. The results obtained
showed that the drug containing microspheres were able to sustain release of the
paclitaxel drug for at lease 50 days with 80% of the loaded drug being released. The
results of the MTT assay proved that the inkjet printing techniques did not alter the
functional properties of the drug [73]. Attesting to the claims of high speed and accurate
deposition, release profiles from the coated stents demonstrated that this technique could
be used to improve drug-loading efficiency as compared to other coating techniques.
A more recent study was conducted to revisit the use of commercial inkjet
printers and ink cartridges, which have been modified for bioprinting applications [74].
Khan et al. sought to prove that when using a modified inkjet printer, the short period of
time in which bio-inks containing proteins are subject to elevated temperatures are
negligible and, in fact, enzymatic activity was present after printing[74].
The need for a more suitable deposition technique for stent coating applications is
desired that can achieve high drug loading efficiency through accurate and localized
printing methods and maintain extended drug release periods. A review of current
deposition methods for biofunctional surface modification applications has been
presented, each with their parameters, benefits, and limitations. It has been shown that,
while each technique has its list of advantages, they are relevant only for certain
applications.

The use of other more conventional deposition methods has been

discouraged whether it be for issue with substrate contamination, lack of control during
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the deposition process, or the possibility of decreasing bioactivity upon being subjected
to heat or some harsh chemical.
Many techniques have been used to coat drug-eluting cardiovascular stents for
drug delivery and a combination of techniques have been used to grow multilayer thin
films. However, none have employed the use of piezoelectric direct-write systems to
develop polymeric coatings for corrosion retardation of magnesium alloys and drug
release of antiproliferative cancer drugs.
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CHAPTER 3
METHODOLOGY
3.1 Overview
Direct-write printing is a novel method that is currently being considered for the
development of targeted and precise polymer coatings for a vast number of biomedical
applications. More specifically, these coatings can serve as protective barriers when
applied to the surface of an implant device and/or be used as a mechanism for the
delivery of anti-proliferative drugs via a coated stent model system. The device or stent
model system consists of the substrate, or biomedical device, in which the coating is
applied, and the coating itself. The nature of the coating can take a variety of forms with
the ultimate goal of achieving a specific release profile.
In the sections to come, a system of experiments is described that will provide an
understanding of the factors which have a profound impact on drug release profiles from
biodegradable thin films fabricated using direct-write printing technologies. A second set
of experiments will describe the effectiveness of polymeric coatings, applied using this
same novel technique, for the retardation of magnesium corrosion.

Details of the

experimental design and process description will be provided followed by a mention of
the possible challenges.
3.2 General Approach
Titanium and its alloys are among the list of metallic biomaterials used to
manufacture surgical implant devices (i.e. stents, orthopedic implants). Other noted
metals include stainless steel and cobalt-based alloys. Metallics as biomaterials are ideal
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due to their ability to resist the fatigue, wear, and fracture sustained from the daily forces
present in the body. The inert presence of these materials also makes them ideal for use
within the body, as they do not present any obvious adverse effects when implanted into
the host site. Many of the cardiovascular stents on the market are made using stainless
steel; however, this dissertation will employ the use of polymer-coated titanium alloy
substrates as a model system to simulate the behavior of drug-eluting stents because of
their strength and biocompatibility in biological environments.
Despite the excellent strength and corrosion resistance properties of titanium for
the manufacture of biomedical devices, there exist some limitations. The most important
is that the surface oxidized layer, which forms after the natural reaction between the
titanium atoms and the oxygen atoms present in body fluids, can also be disrupted by the
metallic ions. Extensive research has been conducted that suggest different ways in
which surface modification of titanium can enhance its biocompatibility. Also, since the
introduction of synthetic and biodegradable polymers for biomedical uses in the early
1900’s, they have been successfully applied in a number of ways to advance the
properties of metallic biomaterials.
Hwal Suh, suggests three classifications of polymeric biomaterials in an article
titled, “Recent Advances in Biomaterials” [75]. The use of biodegradable polymers to
coat metallic materials not only add flexibility to the metal but also provides the
additional benefit of mimicking the functionality of the surrounding tissues present at the
host site. As a result the implanted material is able to remain at the implant site for
extended periods and not pose any immunological threat. Biodegradable polymers have
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the ability to absorb within the body, and in some cases, regenerate lost tissue and or
cells.
An added dimension to the use of biodegradable polymers for coating medical
devices is their ability to sustain and transport medicinal drugs for prolonged drug
release. This is possible due to the natural characteristics associated with a specific
polymer type. The degradation properties of a given polymer type is one factor that has a
significant effect on the time in which it is capable of sustaining drug release. A second
factor is the physiological environment in which the degradation process takes place.
Some commonly used biodegradable polymers for drug delivery include poly-(lactic-coglycolic acid) (PLGA) [76-78], polycaprolactone (PCL) [77,78], and poly(ether urethane)
urea (PEUU) [78].
The listed polymeric biomaterials all possess exceptional biocompatible and
biodegradable properties. As such, they have been approved for use in the human body
specifically for drug delivery applications.

However, research is currently being

conducted to improve its biostability. The degradation rates of these polymers have the
ability to be manipulated such that a desirable rate of release may be achieved [78]. For
instance, PLGA, which consist of the natural monomers lactic and glycolic acid, can be
manufactured in such a way that the ratio of lactic acid to glycolic acid is 75:25 resulting
in a faster degradation rate. Several other advantages to the use of these polymers
support the decision for its use.
Drug release rates not only depend on the polymer type, but also the
pharmaceutical agent and a specified dosage. The types of drugs chosen to deliver drugs
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from cardiovascular stents are numerous, yet they are dependent on the application. For
instance, if the main purpose is to prevent coagulation of blood platelets or increase blood
compatibility of the device then the choice of drug may be Heparin. Chemotherapeutic
drugs have also been used to treat late stage lung cancer patients [79]. A common drug
that is used to inhibit the increased growth or proliferation of unwanted cells around the
stent device is Paclitaxel, also referred to as Taxol [80].
Paclitaxel is an antimicrotubule agent that is used to treat an array of cancers (e.g.
breast cancer, lung cancer, ovarian cancer).

This drug is usually used after other

treatments have been explored and have resulted in failure. Uses of this drug in excess
can lead to depletion of the white blood cells needed to fight infection thus resulting in
fatality. Ideally, this drug would be delivered in small amounts over extended periods of
time, making it the perfect candidate for testing release from biodegradable polymers
[80].
The use of bioinert metallics can eventually lead to foreign body reaction
following implantation due to the body’s inability to recognize the material as one that
compliments normal physiological processes. Thus, magnesium and its alloys have been
identified as a lightweight metallic biomaterial that can withstand the daily forces
imposed by natural body function. It is also the fourth most abundant element found in
the human body making it essential for many of the physiological processes. Magnesium
is an ideal candidate for surgical implant materials because of its ability degrade after
performing its intended purpose without posing any toxic effect to the body.
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Although, magnesium has been identified as an ideal candidate for surgical
implants such as cardiovascular stents, the issue of its fast corrosion rate still remains.
Thus, in a second study we propose that the application of biodegradable polymeric thin
films can be used as a method for retardation of the corrosion process.
The deposition process for loading the drug containing polymer matrix onto the
titanium substrate is one that should also be carefully chosen, particularly for coating
complex structures such as stents. A description of the commonly used deposition
processes for surface coating and modification is found in preceding chapters.
Direct-write inkjet printing offers several advantages to the process of coating
metallic devices such as stents for biomedical applications. One main advantage is the
ability to print local and precise patterns onto three-dimensional structures. With stent
coating the ability to print precise patterns is ideal because of its complex, helical, meshlike design. This technique also prevents webbing of the coating materials, which has
been known to alter the stents functionality. Direct-write printing techniques also permit
biological agents such as drugs and proteins to be deposited without altering their
physical and chemical compositions.
The present research uses the direct-write inkjet printing technique to 1) deposit
biodegradable polymer thin films, laced with the antiproliferative paclitaxel drug, to coat
bioinert titanium substrates and 2) apply polymeric thin films to a magnesium alloy as a
protective barrier for corrosion retardation.
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3.3 Governing Facilities and Equipment
This research is conducted in conjunction with the National Science Foundation
Engineering Research Center (ERC) located in the Interdisciplinary Research Center at
North Carolina Agricultural and Technical State University. The present study is only a
small segment of the ongoing research within the ERC which consists of three
Engineered Systems: (I) Craniofacial and Orthopedic Applications, (II) Cardiovascular
and Thoracic Devices and, (III) Responsive Biosensors and Neural Applications.
Research at the center relies on four enabling technologies: biodegradable metals,
biofunctional surface modification, sensing and controlled degradation and, controlled
release. This dissertation will focus on the ES-II component driven by biofunctional
surface modification and controlled release technologies.
3.4 Fundamental Challenges
Several challenges have been noted, however they are not expected to have a
significant impact on the validity of this research. The first challenge is that, although we
are using planar titanium substrates as the model stent (which are actually three
dimensional), the direct-write system used in this research is not actually capable of
printing on these types of structures. A second challenge is that the consistency between
batches of biological agents and polymers could see small variations in their physical
properties, which could have an effect on the outcome of the experimental results. These
variations can be taken into account in the analysis portion of the research to ensure that
this research effort remains valid.
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Pertaining to the direct-write inkjet printing technique that will be used to coat the
titanium substrate, there are several challenges that may be encountered. For instance,
this technique is limited in the fluids that can be jetted. Fluids having non-Newtonian
properties, which are highly viscous, may not be appropriate for deposition by this
technique. Thus, drug loaded carriers or thin films may not be loaded with a realistic
dosage of drugs needed for treatment. Also, this process is sensitive to the properties of
the fluids being jetted making it difficult to obtain the optimal jetting parameters for a
given fluid concentration. As a result, the jetting optimization process can be time
consuming making it sometimes infeasible to obtain a large number of samples as might
be suggested from conducting a statistical power analysis. Moreover, the optimal jetting
parameters obtained for a given fluid varied from one user or jetting session to the next.
Though not able to be completely eliminated, these challenges were minimized by
designing a protocol for reaching optimal jetting parameters as well as equipment training
sessions.
3.5 Methods and Materials
This section will provide a description of the processes and factors, which are
expected to have a significant effect on the output parameters. The output parameters are
also stated with a description of each to follow.
3.5.1 Direct-write Equipment and Jetting Optimization Process
The deposition technique chosen for this research is a modified inkjet printing
technique designed by MicroFab Technologies Drop-On-Demand Test Stand inkjet
system (MicroFab Technologies, inc., Plano TX). This system consists of a pneumatic
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controller, a MicroFab JetDrive III external waveform generator with heat source,
JetServer software with waveform amplifier, horizontal- and vertical-plane optics system
and a piezoelectric nozzle tip with a 50-micron orifice diameter [48]. The schematic of
the MicroFab test stand is pictured in Figure 3.1.

(a)

(b)
Figure 3.1 (a) Depiction of MicroFab JetLab 4 inkjet printing machine (b) nozzle
printing apparatus and motion panel
Direct-write inkjet printing can be accomplished using one of two different inkjet
technologies, Continuous (CIJ) and Drop-on-Demand (DOD) inkjet printing.
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More

suitable for this research is the DOD (or direct-write) technology. This method requires
electromechanical pulses (or an applied voltage) over a piezoelectric material that causes
the material to deform. The deformation of this material causes an increased pressure
within the nozzle after which a single droplet is ejected [48].
After the droplet is ejected, there is an obvious reduction of fluid volume within
the solution-containing reservoir, thus the solution must be replaced. As the piezoelectric
crystal returns back to its resting state, a negative pressure forces the replacement of the
ejected fluid [48]. A list of the input parameters required to characterize the above
described process is in Table 3.1.
Table 3.1 List of piezoelectric Direct-write parameters
Piezoelectric Direct-Write Process Parameters
1.
2.
3.
4.
5.

Frequency
Jetting Voltage
Waveform (driving signal)
Print head Design
Jetting Fluid Properties
It is desired to optimize the jetting process to achieve a steady stream of

uniformly shaped droplets for the deposition of thin film coatings onto prepared titanium
substrates. The parameters, which influence this optimization process, include: pulse
waveform, print head design, and jetting fluid properties (Figure 3.2). A description of
the print head design has been discussed previously. It is designed to include a nozzle
orifice as low as 10 micrometers in diameter where it is expected that the variations of the
droplet size (diameter) distribution from the orifice diameter may be neglected.
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Figure 3.2 Direct-write process parameter relationship
The pulse waveform requires its own set of parameters that can be optimized for
the manipulation of drop size and speed, jetting sustainability, drop placement and drop
uniformity. The waveform parameters include the frequency, positive/negative jetting
voltage, rise time, dwell time, fall time, and final rise time denoted by f, +V/-V, TR, TD,
TF, and TFR, respectively. Where the jetting voltage is the optimal voltage (+V) applied
causing deformation of the piezoelectric material. –V is usually set at 0, setting the
voltage back to 0 and returning the material back to its initial resting state [81].
The rise and fall times with respect to the characterization of the pulse waveform
are the time for the driving signal to reach the optimal amplitude (voltage) and the time
for which it takes to decrease the voltage back to its original state. The dwell time that
the optimal voltage is applied to the piezo material and the frequency refers to the
number of drops jetted over a given time span. Figures 3.3 (a) and (b) below depicts the
resulting waveform for piezoelectric direct-write processes and the MicroFab JetServer
interface used to vary these parameters respectively.
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(a)

(b)
Figure 3.3 (a) Depiction of JetLab interface (b) pulse waveform formation
Much research has been conducted on the manipulation of the waveform shape
and parameters to determine their effects on the jetting process. Such a parameter that
contributes greatly to the success of the jetting process is jetting stability. The jetting
stability is greatly affected by the retraction of the meniscus (fluid surface at the nozzle
tip), which is directly related to the reservoir pressure resulting from TF.
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Polymer

buildup at the nozzle tip negatively affects the success of the jetting process. In literature
this is referred to as puddling and is directly related to the frequency of droplet
accumulation.
A final parameter having a significant effect on the jetting process is the jetting
fluid chosen and its associated fluid properties [82]. The fluid properties significantly
affects the jettability of a substance, which is the fluid’s ability to maintain a jet stream of
droplets for an extended period of time (e.g. two to three hours). Jettable fluids can be
broken down into two categories: Newtonian and Non-Newtonian fluids [82]. This
research deals with polymeric solutions, which display Non-Newtonian properties, that
is, fluids with high viscosity, density, and surface tension values.
The manipulation of fluid properties can be obtained by varying fluid
concentration (in this case, polymer concentration) given a solid polymer percentage
(weight, %) and solvent (volume, mL) to obtain a weight/volume solution.

More

specifically, the concentration of a given polymer such as poly(lactic-co-glycolic acid)
(PLGA) used in our experiments, can be altered by adjusting its ratio of lactic and
glycolic acid to obtain a higher concentration of solution thus resulting in a higher
viscosity. The effects of the fluid properties directly relate to tail break-off of the jetting
solution. Also, a more viscous solution will have a longer tail (break-off period), which
will slow the drop speed.
Residual vibrations may occur even after a single drop has been ejected and could
influence the nature in which the resulting drops are ejected.

Robustness against

disturbance deals with the optimal parameter settings and system abilities in dealing with
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such disturbances as dust and air bubbles that could stop the jetting process. Lastly,
aging of the piezo material could have a profound effect on the optimal achievable jetting
process parameters. There are many other operational issues that could limit the
optimality of the direct-write printing process, however, these issues were controlled to
the best extent possible.
3.5.2 Characterization of Coating Morphology and Thickness
Surface morphologies were characterized using optical and scanning electron
microscopy. The use of this technique allowed for monitoring any changes regarding the
coating surface, not only before and after optimal release has occurred, but also to track
any possible changes in thickness during sample collection periods. This is due to the
non-destructive nature of the imaging process.

For further characterization, SEM

imaging may be used before and after sample testing periods but only for general
characteristics across groups of samples at the same stage in the testing process. This is
attributed to the destructive nature of SEM sample processing. The film thicknesses of
the drug loaded polymeric coatings were evaluated by using both scanning electron
microscopy and optical profilometer, respectively where the polymer film was cut to
reveal the cross-section areas and thickness profiles. The SEM technique was also used
for qualitative characterization of surface interaction between blood platelets and drug
loaded polymer coatings. Images resulting from this technique were also used to quantify
adhesion of the platelets to the surface.
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3.5.3 Characterization of Drug Release
Release kinetics for the characterization of release profiles were measured using
Ultra-Violet Spectrophotometry techniques. This technique is generally used to detect
traces of a given substance within a sample by transmitting a source of light through its
contents to measure its absorbance. The absorbance is measured over a given wavelength
where a maximum absorbance is said to exist. For example, literature states that the
wavelength for which the maximum absorbance reading for Paclitaxel may be obtained is
somewhere in the realm of 227 nm. This wavelength value for achieving the optimal
absorbance readings for the samples were validated using a Shimadzu UV-2450
Spectrophotometer to ensure repeatability. Performing serial dilutions on concentrated
paclitaxel solutions and gaining absorbance readings from the UV spectrophotometer, we
were able to develop a standard curve. The process described allowed us to calibrate and
compare the release values on the standard curve to determine total concentration of the
drug, which was released.
3.5.4 Selection of Materials
The placement of foreign bodies, specifically bare metal stents (BMS), within the
human body can pose serious threats at the implant site. Moreover, the rapid growth of
undesirable smooth muscle cells triggered by the presence of the foreign body is found to
be a main cause of late-stage restenosis. The collapsing of the cardiovascular stent, due
to excessive forces is caused by neointimal hyperplasia. Generally cardiovascular stents
and other surgical implant devices are manufactured using metallic materials, such as
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stainless steel, nickel, and titanium, which are not recognized within the physiological
environment.
This research focuses particularly on the manufacturing and design aspects of
drug delivery systems (DDS’s). Thus, an actual cardiovascular stent will not be used. A
bare titanium substrate will be used as a substitute. For the characterization of the
controlled release coatings, 10x10 mm coupons were used primarily to scale up the drug
concentration so that absorbance detection was possible. For biological testing, the
titanium substrates used were round having an approximate diameter of 6 mm. The
round shape of the substrates is necessary to conduct an MTT assay for the determination
of cell proliferation later on in this study.
For the characterization of polymer coatings for corrosion inhibition, a
magnesium alloy with the composition (Mg:90%, Zn:8.9%, Ca:0.5%, rest impurities) was
smelted as ingots within an inert environment (argon) in our laboratory. The Mg alloy
was used as-cast without further processing such as cold work or heat treatment. A flat
piece (10mmx10mmx2mm) of this Mg alloy was casted into a disc-shaped epoxy resin so
that only the top surface of the Mg alloy was exposed. This is because we are interested
in studying the corrosion behavior of Mg alloy with different polymeric coatings on only
the top surface without affecting the corrosion of the other sides. The sample top surface
was then polished to eliminate the magnesium oxide layer.
The general expectations of a biopolymer suitable for coating cardiovascular
stents is that 1) it must be biocompatible; 2) it must demonstrate selective permeability;

49

3) it must have the ability to biodegrade; and 4) it must demonstrate high mechanical
strength. A depiction of the aforementioned (Figure 3.4) and a brief description follows.

Figure 3.4 Characteristics of biopolymer for stent coating applications
Biocompatability of a polymer can be measured in a number of ways. One
common measurement is to count the number of plasma protein, or blood platelets, that
accumulate at the surface of the polymer over a period of time. If amassing is excessive
than it can be concluded that that the polymer is biologically incompatible. A second
qualitative measure is excessive tissue growth at the implant site.

This leads to a

discussion of mechanical strength.
In keeping perspective of the excessive tissue build up around the bare metal
stent, the remaining requirements of a biodegradable polymer is further discussed. The
application of a thin film biopolymer coating displaying high mechanical strength could
aid in maintaining the structural vigor of the of the stenting device for lengthier periods
of time. Alongside good mechanical strength is selective permeability. The polymer
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membrane should maintain some level of control over what is allowed to cross it and the
rate at which any substance (or drug) is allowed to do so. In a practical sense, the drug,
paclitaxel, is expected to permeate through the polymer membrane at a controlled rate to
slow the growth of the smooth muscle cells. The decreased rate of cell growth due to the
controlled release of paclitaxel along with increased mechanical strength is said to
decrease the probability that restinosis will occur.
The preparation stages are expected to be one of the most vital segments of the
series of components involved. This is due in part to the extremely high volatility of the
materials that will be used. Aside from that, the dosages of paclitaxel to be embedded
into the polymer are so small that special care must be taken in making sure that all
materials are measured accurately in order to decrease variations of the results obtained.
Recall that paclitaxel has been chosen to simulate release profiles for alternative
drug-polymer systems. Paclitaxel (taxol) is a cancer treatment compound, which is
derived from the bark of taxus brevifolia found in the Pacific. Taxol is commonly used
to treat breast, ovarian, and late stage lung cancers as well as occurrences of restenosis
within the arterial wall.
Though recently there has been much controversy to the use of this drug, its use
as an inhibitor of the rapid division of undesirable cells has proven effective for the
treatment of rapidly growing tumors and neointimal hyperplasia.

The compounds

effectiveness can be attributed to its ability to inhibit the breakdown process of
microtubules, a major component of the cell division process. The molecular breakdown
of paclitaxel is depicted in Figure 3.5 below.
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Figure 3.5 Breakdown of a single molecule of paclitaxel
The uses of paclitaxel for the drug-loaded polymer thin film coating is desirable
for stent coating applications mainly because it has demonstrated properties such as anitproliferative and anti-inflammatory on cell interaction.

Drug-eluting stents, using

paclitaxel, are necessary to inhibit unwanted cell growth that will prevent the renarrowing of the arterial wall due to this growth.
Preceding the discussion of Taxol’s dissolution mechanism, the mention of the
difficulties in characterizing these properties is deemed necessary. It is important to
understand the process by which this drug is obtained and how drug development can
contribute to variations of its dissolution properties. For instance, a recently reviewed
article attributes the challenges of describing the dissolution of paclitaxel to variations
between batches of the drug resulting from the different environmental factors of which
the drug was subjected. Examples of factors that influence these variations include;
weather, soil composition, water and sun. It is inferred that these factors could indirectly
impact the repeatability of dosages required to treat tumor growth and, in our case,
neointimal hyperplasia.
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Aside from possible variations between batches of the drug, paclitaxel has
demonstrated low solubility within the physiological environment. This phenomenon
been demonstrated in vitro, via studies of dissolution after incubation in phosphate buffer
saline (PBS) solution at 37 degrees Celsius to simulate physiological environments as
well as in vivo in numerous rat models. Taxol is generally mixed with harsh solvent to
relax its dissolution. It has been noted in recent in vitro studies characterizing the
insolubility of paclitaxel that increased concentrations of the drug between 1% and 5%
w/v, homogeneously dispersed in aqueous polymer solution, begin to crystallize
following polymerization after a period of days. This is a phenomenon that was realized
in the preliminary studies of this research. Figures 3.6 (a) and (b) below depict the
spherical shape of crystallized paclitaxel by scanning electron microscopy (SEM)
technique (courtesy of the Engineering Research Center at North Carolina A&T State
University). Images were taken at 800 x and 4,000 x magnification respectively. The
reduction of drug particle size is a good aim in future studies of taxol release towards the
improvement of solubility.

53

(a)

(b)
Figure 3.6 (a) Precipitated taxol beads of PEUU surface 800X (b) 4,000X
For each of the proposed systems variations of polymer and drug concentration,
as well as thickness may be applied to achieve the critical viscoelastic and mechanical
properties desired for optimal drug release. It is important to note that the optimality of a
given drug release profile is dependent on the application. A list of parameters affecting
the viscoelasticity of a given polymer solution is provided in the Table 3.2 below
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followed by a diagram (Figure 3.7) depicting the influence of viscoelasticity in drug
release.
Table 3.2 List of viscoeleastic parameters
Parameters of Viscoelastic Polymer Solutions
1.
2.
3.
4.
5.
6.
7.
8.

Temperature
Pressure
Time
Polymer Chemical Composition
Molecular Weight
Crystallinity
Solvent Dilution
Polymer/Mixture Composition

Figure 3.7 Influence of viscoelastic properties on drug release
The viscoelastic properties strongly influence the polymer systems ability to
maintain structural and mechanical drug efficiency. However, there are other factors that
contribute the integrity of these designed systems. Some of the most influential factors
include particle size distribution, physical state and concentration profile of the drug with
the polymer thin film, and dissolution and diffusion properties of the drug. An effort to
maintain structural and functional integrity has been considered in the design of the
proposed polymer thin film systems.
A review of literature regarding the dissolution and diffusion properties of taxol in
PCL and PLGA, two other biocompatible polymeric materials, is presented. S. Dordunoo
et al. characterized the release of taxol from PCL microspheres (Dordunoo et. al, 1995).
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It was determined that crystallinity of the polymer is said to be lower with increased taxol
loading which resulted in reduced times for degrading.

Furthermore, accumulated

crystallized taxol particles resulted from increased drug loading (5% to 10% w/v), again,
a phenomenon that was validated in our studies. This is said to provide a pathway,
initiating at the polymer surface, which could be responsible for the fast paced dissolution
of the drug. This is an indicator that the drug loading exceeds the capacitated efficiency
of the polymer solution (saturation) or a lack of homogeneity of the drug-polymer
solution. The findings for taxol release from PLGA nanoparticles demonstrated similar
results, with the exception that faster release rates were obtained.
The present study uses a biodegradable polymer, polyetherurethane urea (PEUU)
coating, for characterizing the release of a chosen drug, namely paclitaxel for simulating
drug release. PEUU is chosen as a candidate polymer for testing due to its excellent
biocompatibility and high mechanical strength.
The use of drug-loaded polymers as thin film coatings for the purposes of
conducting therapeutic sessions is eminent for cardiovascular stenting applications. The
combination of the biopolymer and curative drug work together as a drug delivery system
(DDS) to administer treatment for ailments such as neointimal hyperplasia, the fast-pace
growth of unwanted cells, restenosis, as well as late-stage lung cancer patients. It is
desired to achieve a DDS, via cardiovascular stent device, that can maintain compatibility
within the physiological environment yet retain its ability to achieve drug release over
extended time periods.
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Along with PEUU, PLGA and PCL were chosen to coat alloyed magnesium
substrates to study the controlled corrosion mechanism. PLGA is chosen here because of
its excellent biodegradability and biocompatibility properties.

It has already been

approved for applications in developing therapeutic and implant devices due to the notion
that it poses little to no toxic by-products to the body.

In fact, PLGA undergoes

hydrolysis within the body to produce the natural monomers, lactic and glycolic acid,
which are by-products of various metabolic pathways found in the body.

An added

benefit of its use is that degradation rates can be manipulated by changing the monomers
ratio (lactic: glycolic acid). For example, PLGA 70:30 consists of 70% and 30% of lactic
and glycolic acid respectively. It is known that higher amounts of glycolic acid decrease
the time for degradation.
The second polymer, PCL, is polyester, which degrades by hydrolysis of its ester
linkages. The degradation rates here are said to be much slower than that of the other
two;

however,

this

polymer

also

demonstrates

excellent

biodegradable

and

biocompatibility. PCL has also been approved for uses in the human body by the FDA
for applications such as drug delivery devices and adhesion barriers. An added benefit is
that PCL is less viscous as a solution compared to the others making it an ideal candidate
for printing using our novel direct-write printing technique. Lastly, as mentioned earlier,
PEUU is chosen as a candidate polymer for testing due to its excellent biocompatibility
and high mechanical strength.
PCL as well as PLGA were not only chosen because of their excellent
biocompatible and biodegradability, but also because they provide other advantages to
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the development of polymer thin film layers. For example, the FDA has approved PCL
for barrier uses in biological components and PLGA degradation rates can be altered
through systematic manipulation of its molar ratio.
3.6 Controlled Release Coatings (Phase 1)
Controlled release coatings are fabricated to suit a variety of different
applications. More specifically, the controlled release of various biological agents from
biodegradable polymer coatings to treat a vast number of physiological ailments is of
particular interest. The use of the Direct-Write inkjet technique as a mechanism for
developing controlled release coatings offers a variety of advantages for coating surfaces
containing biological and pharmaceutical reagents [48]. For instance, this technique uses
a data-driven pressure source for deposition of material onto a given substrate, where
other fabrication techniques use electricity, which may compromise the integrity of the
biological substances [48]. Other techniques such as spin coating and dip coating are not
able to accommodate the complex structures that are usually required by surgical implant
devices. None of the deposition techniques discussed earlier offer the ability to deposit
target specific coatings, maintain the integrity of the deposition material, and eliminate
cross-contamination of materials.
The need for a coating technique that encompasses all of the benefits mentioned
above is necessary to develop controlled release coating where spatial requirements can
be specified to develop coatings with specified porosity and degradation features. In this
research, the intent was achieve a variety of drug release profiles that could be tailored to
support the needs of a given drug delivery application. Here, the drug concentration and
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layers of coating material were varied to assess coating specifications resulting in a
steady state release throughout its intended time of function. This result would be
desirable for ailments requiring extended therapeutic sessions such as neointimal
hyperplasia, using an anti proliferative such as Paclitaxel, following placement of a
cardiovascular stent device [6]. Coatings having a more profound initial burst phase were
also attempted.

These coatings would be more suitable for applications such as

antimicrobial and/or antifibrotic therapy were the majority of the reagent is required in
the initial stages of treatment to treat infection at the implant site and promote healthy
wound healing [83-84].
3.6.1 Materials Synthesis
Traditionally, cardiovascular stents are fabricated from stainless steel (SS) or
titanium (Ti) materials. In this research, a metallic substrate (Titanium) was used to
mimic the surface properties of the Ti stent. A 10mm x10mm Ti sheet was deposited with
drug loaded polymeric formulation to evaluate the drug release kinetics and coating
morphology as described herein.
Biodegradable polyester urethane urea (PEUU) was synthesized at a proprietary
source (University of Pittsburgh) and obtained for the experiments. The PEUU was
dissolved in hexiflouroisopropanol (HFIP) solvent (Sigma Aldrich) and shaken
vigorously until homogenous polymer solutions of 1%, 1.5%, and 2% w/v were obtained.
These polymer concentrations were chosen based on the rheological properties of fluids
to ensure that they were “jettable” from the direct-write inkjet system. Paclitaxel (Taxol)
drug (LC Laboratories) was added at 5% and 10% w/w of the respective PEUU
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concentrations within the biopolymer solutions. The drug paclitaxel is an inhibitor of the
rapid division of malignant cells and has been proven effective for the treatment of
rapidly growing tumors (cancer cells) and neointimal hyperplasia. Prolonged release of
the drug from multilayered thin film coatings on cardiovascular stents is proven to be
beneficial against this malady.
3.6.2 Sample Fabrication
Biopolymer solutions with varying concentrations of PEUU and Taxol were
deposited on titanium (Ti) substrates using a customized direct-write system (MicroFab
Technologies Inc., Plano, TX). The unit consisted of a pneumatic controller, a JetDrive
III external waveform generator, JetServer software with waveform amplifier, horizontal
and vertical plane optic system, and a piezoelectric microvalve nozzle with a 50 micron
orifice. Figure 3.3 (b) shows the pulse waveform applied to the nozzle to generate
monodisperse droplets. Optimal jetting parameters for consistent deposition were chosen
by adjusting the voltage, frequency and pulse waveform. A CCD camera with
microscopic zoom lens was used to characterize droplet formation. Further, a motion
controller was programmed to create a raster pattern that coats the titanium substrate
uniformly. Each layer was allowed to dry before the next layer was deposited. Samples
with 10 and 20 layers respectively, were deposited to obtain surface morphology data and
release kinetics profiles.
3.6.3 Characterization of Release
Drug release profiles were characterized using an ultraviolet-visible spectrum
(UV-Vis) spectrophotometer (Shimadzu UV-2450). Samples were placed in 3mL of
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Dulbecco’s Phosphate Buffer Saline (DPBS) to initiate drug release. 10% v/v of ethanol
was mixed in the DPBS (Fisher Scientific) to obtain accelerated release kinetics of the
drug. The solution was shaken for several minutes to ensure a homogenous mixture. The
peak absorbance of paclitaxel was confirmed at 230nm. Coated Ti sample readings were
obtained at this wavelength after being shaken in an incubator shaker bath at 37°C for 2
hours. DPBS solutions from the Ti samples were extracted into a micro-cuvette to
observe the absorbance readings for different polymer and Taxol concentrations.
Readings were taken every two to three hours for the first twenty-four hours and daily
thereafter. Release kinetics results were recorded for a period of 35 days.
3.7 Controlled Release Coatings (Phase 2)
3.7.1 Experimental Design and Analysis
Release profiles were to be obtained for a total of four different drug-loaded
polymer systems using Polyester urathane urea (PEUU) and the bioreactive agent
Paclitaxel (Taxol). Two primary factors were controlled to determine their effects on the
release profiles obtained. The first factor was drug concentration. Concentration was
tested at two levels, 5% and 10% weight per volume. Lastly, the layer thickness, which
corresponds to the number of passes, was tested at two levels, ten (10) and twenty (20)
passes, respectively Table 3.3.
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Table 3.3 Phase 2 descriptions of experiment types for controlled release coatings

A total of three samples were coated for each experiment. A single experiment
consisted of a specified drug concentration having a certain layer thickness.

For

example, 0.5% PEUU loaded with 5% taxol at 10 passes describes one experiment where
0.5% PEUU loaded with 10% taxol at 20 passes describes another.
The dependant variables in the study of release profiles are identified as the
percentage burst release and the total amount of the drug released at the end of the sample
collection period. The initial rate of release corresponds to the slope of the release profile
in the initial stages. This initial rate is relevant to the speed at which the initial burst
takes place from the time the release period is initiated until the time it reaches a steady
rate of release. The percentage burst release corresponds to the ratio of drug that is
released and drug loaded during the initial burst period. The total release remains as
stated above.
The basic research question is as follows, “Can direct-write inkjet printing
technique be used as a mechanism for depositing uniformly distributed layers of drugloaded polymer thin films and furthermore, can tunable drug release profiles be obtained
over extended time periods by varying the two main input factors (drug concentration
and coating thickness)?” A set of more specific research questions was extracted that
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was expected to help answer the basic research question. These questions are stated
below followed by their respective null and alternative hypothesis statements.
1. Does drug dosage and coating layer thickness have a significant effect on the drug
release profile? (Phase 2a)
2. Does drug dosage and coating layer thickness have a significant effect on cell
inhibition? (Phase 2b)
3. Does drug dosage have a significant effect on blood compatibility? (Phase 2c)
For Phase 2a, a 2x2 factorial design was used to determine the main and
interaction effects of the two experimental factors (i.e. drug dosage and coating
thickness) on the response variables. There were a total of four experiment combinations
and each was replicated twice to assess error. Thus, giving a total of 8 experiment trials.
The following null and alternative hypotheses were formed:
H01 = the sample means for drug dosage are equal
H02= the sample means for number of layers are equal
H03 = there is no interaction effect
H11 = at least one of the sample means for drug dosage is different
H12= at least one of the sample means for number of layers is different
H13 = an interaction effect is present
In Phase 2b, a one-way ANOVA was conducted to determine if there was a
difference in means between each experiment type and its respective control. There were
a total of 8 treatment conditions (4 controls and 4 treated surfaces) and each was
replicated 4 times giving a total of 32 runs. The metabolic means of samples containing
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10 and 20 layers with a 5% w/w drug loading were compared to the metabolic means of
samples having 10 and 20 layers of PEUU with no drug respectively. Also, the metabolic
means of samples containing 10 and 20 layers with a 10% w/w drug loading were
compared to the metabolic means of samples having 10 and 20 layers of PEUU with no
drug respectively. Lastly, the metabolic means of each of the experiment groups was
compared with the mean metabolic index of cells cultured on Tissue Culture Polystyrene
(TCPS). The following null and alternative hypotheses were formed:
H0 = the sample means for all experiment condition are equal
H1= at least one of the sample means is different
For Phase 2c, a one-way ANOVA was used to determine if drug concentration
has a significant effect on the blood platelet count. For this experiment each of the
samples were coated with 20 layers of PEUU and only the drug concentration were
varied. There were three levels, which were 5% w/w, 10% w/w and no drug (low
control). The experiment was replicated three times for considering error resulting in a
total of nine replications. The following null hypothesis was formed to state that there is
no difference between the mean platelet count of each sample group. The associated
alternative hypothesis states that there exists a difference between means of the sample
groups:
H0 = the sample means for drug dosage are equal
H1= at least one of the sample means for drug dosage is different
3.7.2 Experimental Procedure
3.7.2.1 Materials Synthesis
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Polyester urethane urea (PEUU) and the metallic substrate (titanium) were
generously donated by Wagner Laboratory at the McGowan Institute for Regenerative
Medicine.

Paclitaxel, >99.5% (taxol) was obtained from L C Laboratories and

hexaflouor-2-propanol, >99.8% (HFIP) was obtained from Sigma-Aldrich. Under a hood,
20 milliliters of HFIP solvent were measured by micropipette and placed into a glass
vessel. For experiment sets one and three, 0.5% w/v (0.1 grams) of solid PEUU polymer
was weighed using a Metler Toledo AX DeltaRange digital scale and fully dissolved in
the previously measured HFIP to obtain a homogenous HFIP/PEUU solution. A 5% w/w
(0.005 grams) dosage of paclitaxel was then weighed using a digital scale and dissolved
into the HFIP/PEUU solution.
For experiment sets two and four, 0.5% w/v (0.1 grams) of solid PEUU polymer
was weighed using the Metler Toledo AX DeltaRange digital scale and fully dissolved in
a separate glass vessel containing a previously measured 20 milliliters of HFIP to obtain a
homogenous HFIP/PEUU solution. A 10% w/w (0.01 grams) dosage of Paclitaxel was
then weighed using a digital scale and dissolved into the HFIP/PEUU solution. The
solutions were shaken vigorously in a mini shaker to ensure that a homogeneous
HFIP/PEUU/Paclitaxel solution was obtained. The solutions were filtered using 0.22micron micropore Teflon filters into two milliliter jetting reservoirs and refrigerated until
ready for use.
A third solution was prepared consisting of 0.5% w/v HFIP/PEUU mixture. This
solution did not contain the drug, paclitaxel and was stored for use as a control for the
cell inhibition and blood compatibility testing samples.
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As a release media, DPBS containing 10% ethanol was chosen to simulate
accelerated release. One package containing 9.6 grams of Dulbecco’s Phosphate Buffer
Saline (DPBS) powder (Fischer Scientific) was dissolved in 900 milliliters of deionized
water to make a 900-milliliter DPBS solution. 100 milliliters of pure ethanol was then
measured and mixed with the DPBS solution to obtain a 10% DPBS plus ethanol
solution. The solution was shaken for one minute to ensure a homogenous mixture.
3.7.2.2 Sample Preparation and Coating
Titanium sheets cut into 10x10 mm coupons. The samples were submerged into a
glass vessel containing pure acetone and sonicated in a bath sonicator for ten minutes.
After ten minutes the coupons were removed from the acetone and submerged into
ethanol. The samples were again sonicated for another ten minutes for cleaning. The
sample coupons were removed and air-dried.

Each sample was assigned a sample

number and weighed for its initial starting weight.
The customized direct-write system (MicroFab Technologies Inc., Plano, TX)
described above was used to determine the appropriate jetting parameters for each of the
biopolymer solutions. The unit consisted of a pneumatic controller, a JetDrive III external
waveform generator, JetLab software with waveform amplifier, horizontal and vertical
plane optic system, and a piezoelectric microvalve nozzle with a 50-micron orifice. Using
the JetLab interface, the appropriate pulse waveform for consistent droplet formation was
characterized by manipulating the rise, dwell, and fall times, as well as the voltage and
pressure. The JetLab interface includes a motion control component as well as a pattern
monitor, which allows us to control length, width and thickness of the coating pattern by
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adjusting the step size between droplets. A CCD camera with microscopic zoom lens
was used to characterize droplet formation.
Thin films were deposited onto the 10x10 titanium substrates using the directwrite inkjet printing technique. The drop-on-demand (DOD) procedure is a non-contact
technique that employs the application of electrical pulses to a piezoelectric material in
order to create uniform droplets of a desired solution. A schematic of the deposition
pattern (not drawn to scale) can be seen in Figure 3.8 below.

(a)

(b)
Figure 3.8 Deposition pattern using array of array command (a) top (b) iso view
An array of arrays command, using the newly acquired Jetlab 4 interface, was
used to deposit the printed droplets onto the substrates. Figure 3.9 depicts the interface
with input parameters that result in associated pattern, which accompanies it. The step
(distance between drops) and pitch (drop diameter) sizes can be optimized to obtain more
evenly distributed coating layers. This is depicted in Figure 3.10. The input parameters,
67

which are required, are the origin of the array which is essentially the starting point of the
pattern based on an absolute coordinate system, the step size within arrays (x,y), number
of steps per array (x,y), offset between arrays (xy), number of arrays (x,y) and angle. A
0.05 mm step size was employed when coating our samples. The number of layers was
input in the “number of arrays” and the offset between origins was set to zero.

Figure 3.9 Depiction of JetLab print pattern interface
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Figure 3.10 Schematic of step and pitch distance
3.7.2.3 Characterization of Release
To initiate accelerated release of the taxol drug, each sample consisting of the
titanium alloy coated with the PEUU and Paclitaxel thin film was placed into a glass
vessel containing two milliliters of Delbuco’s Phosphate Buffer Saline (DPBS) + 10%
Ethanol solution. The vessel and its contents were then placed into a Thermo Scientific
Shaking Bath (Figure 3.11), set at 37 degrees Celsius and rotating at 50 rpm (mimicking
conditions of the human body). After the first 2 hours, the first reading was obtained to
determine release of the anti-proliferative cancer drug. Following the first sample reading
at two hours, readings were obtained four more times during the course of the first 24hour period at 4, 6, 22, and 24 hours. Sample readings were again obtained at 26, 48, 72,
98, 170, 242, and 338 hours. Further readings were taken every 2-3 days based on
release trends.
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Figure 3.11 Depiction of thermo scientific shaker bath

Figure 3.12 Depiction of Shimadzu UV-2450 spectrophotometer
Release kinetics for the characterization of release profiles were measured using
Ultra-Violet spectrophotometry techniques. This technique is generally used to detect
traces of a given substance within a sample by transmitting a source of light through its
contents to measure its absorbance.

The absorbance is measured over a given

wavelength. Literature states that the wavelength for which the maximum absorbance
reading for paclitaxel may be obtained is around 227 nm (Willey et. al, 1993). The
wavelength values found in literature for achieving the optimal absorbance readings for
the samples were validated to ensure repeatability. Performing serial dilutions of the
concentrated substances and gaining sample readings from the UV spectrophotometer
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resulted in the development a standard curve. The release values obtained were then
compared to the release values on the standard curve.
As described in earlier sections the Shimadzu UV-2450 Spectrophotometer
(Figure 3.12) was used for our sample data collection. During these periods, sample
aliquots from each of the vessels containing the titanium samples were extracted and
pipetted into a microcuvette. The microcuvette was then placed into spectrophotometer
and the absorbance peaks were detected and recorded.
3.7.2.4 Blood Collection and Compatibility Test
The care and use of laboratory animals was performed according to NIH
guidelines (Wagner Lab, University of Pittsburgh). Fresh ovine blood was collected from
healthy ovines by jugular venipuncture into a syringe containing heparin (Hep 6U/ml).
Each of the samples, PEUU containing no taxol, PEUU containing 5% taxol, and PEUU
containing 10% taxol, were placed into blood collection tubes and containing the
heparinized ovine blood and incubated at 37º C on a hematology mixer with continuous
rocking. This is depicted in Figure 3.13.
Following the blood contact procedure, the samples were rinsed with PBS. To fix
the samples surface containing the adhered platelets, the samples were immersed in a
2.5% glutaraldehyde solution for two hours at 4ºC. The samples were then serially
dehydrated by increasing ethanol concentrations and coated using sputter deposition with
gold/palladium. Each sample was then observed using scanning electron microscopy.
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Figure 3.13 Blood platelet deposition in hematology mixer
The number of platelets deposited on the samples surfaces was quantified by a
lactate dehydrogenase (LDH) assay with an LDH Cytotoxicity Detection Kit.

The

number of cells/mm2 was determined for each sample in the sample group and the
average and standard deviation obtained. The statistical significance between the sample
groups was determined using ANOVA followed by post-hoc Newman-Keuls testing of
specific differences based on the hypothesis formally stated.
3.7.2.5 Cell Growth Inhibition
All coated titanium disks (6 mm diameter) were placed in a 96-well cell culture
plate and then sterilized under UV irradiation for three hours in a biological hood. Tissue
cultured polystyrene (TCPS) and uncoated titanium disks were set as controls. 2*103 rat
smooth muscle cells (RSMCs) per well were seeded on the sample surface, and cell
culture medium (DMEM supplemented with 10% FBS and 1% antibiotics) was
exchanged every two days. MTT assay was performed to detect cellular viability at one,
four and seven days. Briefly, 20 uL MTT solution (3 mg/mL) was added into the culture
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medium in a well. After 4 hours in an incubator at 37ºC, the medium was completely
removed and 200 uL of DMSO was added to dissolve the produced blue crystal. The
absorbance was detected using a 150 uL dye solution at 540 nm on a UV spectrometer.
Four samples were used at each time point for each group.
3.8 Polymer Coatings for Controlling the Corrosion of Mg Alloys (Phase 1)
Biofunctional coatings are necessary to suit a variety of different medical
applications. The use of the direct-write inkjet technique as a mechanism for enhancing
the structural integrity of a given biomaterial via biofunctional coatings, namely
magnesium and its alloys, is of growing interest. Uses for magnesium as a biomaterial
offers several advantages and can spread across a number of applications. For instance,
magnesium is essential to over 300 physiological functions within the body [85] and has
also been identified as a potential biomaterial to facilitate bone growth and repair due to
proven similarities of mechanical strength with the cortical bone [86].
Direct-write deposition can be used to fabricate coatings where spatial
requirements can be specified to develop coatings with specified porosity and
degradation features for inhibiting the corrosion of magnesium alloys. In this study, the
intent was to investigate a variety of polymer coatings having various rates of
degradation. Here, the polymer type and layers of coating material were varied to assess
coating specifications for applications in corrosion protection and controlled release of
magnesium alloys. Corrosion protection is essential to ensure that a polymer coating is
applied, which can extend the life of the surgical device until its intended function is
completed [86]. The controlled release of magnesium in the trachea can be beneficial in
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relaxing airway cells when exposed to an environment causing inflammation [87].
Magnesium deficiencies have also been linked to cardiovascular disease.

Thus,

controlled release of magnesium via controlled release coatings can offer some benefit
when applied to tracheal and cardiovascular stent devices [88].
3.8.1 Sample Preparation
A magnesium alloy with the composition (Mg:90%, Zn:8.9%, Ca:0.5%, rest
impurities) was smelted as ingots within an inert environment (argon) at our laboratory.
The Mg alloy was used as-cast without further processing such as cold work or heat
treatment. A flat piece (10mmx10mmx2mm) of this Mg alloy was casted into a discshaped epoxy resin so that only the top surface of the Mg alloy was exposed. This
process is because we are interested in studying the corrosion behavior of Mg alloy with
different polymeric coatings on only the top surface without affecting the corrosion of the
other sides. The sample top surface was then polished to eliminate the magnesium oxide
layer. Two biodegradable polymer types, poly(lactic-co-glycolic acid) (PLGA) and
polycaprolactone (PCL), were chosen based on their desired chemical and mechanical
properties as corrosion barriers. They offer advantages that include tunable degradation
rates based on the adjustable chemical composition of lactic and glycolic acids in PLGA
to lengthen or shorten degradation periods, lack of toxic response at the implant sites, and
their ability to be metabolized by the body. PCL is a tough biodegradable polyester with
applications in tissue engineering and drug delivery. Both polymers were dissolved at 1%
w/v in appropriate solvents to possess suitable viscoelastic properties for the coating
process.
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3.8.2 Sample Coating Procedure
A custom direct-write inkjet setup (Jetlab4 - MicroFab Technologies, Plano, TX)
was used to coat the samples. A 50 µm nozzle was used to deposit twenty (20) layers of
polymer coating at different pitch distances (inter-drop distance). A single layer consisted
of a raster pattern of continuously deposited droplets as shown in Figure 4.14 a and b.
Both polymers (PLGA and PCL) were coated with different pitch distances (50µm and
100µm) as shown in Table 3.4. One sample was left uncoated (bare Mg alloy) and used
as the control. It was hypothesized that the coatings with larger pitch distances (100µm)
would result in porous structure and higher corrosion rates when exposed to the media.

(a)
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(b)
Figure 3.14 (a) Schematic of magnesium cast in epoxy resin material (b) schematic
of deposition pattern
Table 3.4 Phase 1 description of experiment types
Sample No.

Polymer Type

Pitch Distance (m)

1

Bare (uncoated)

N/A

2

PLGA

50

3

PLGA

100

4

PCL

50

5

PCL

100
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3.8.3 Sample Immersion Test (Weight Loss)
A 0.9% (NaCl) simulated body fluid (SBF) solution was prepared to mimic the
human physiological environment. For each of the five samples, 30 ml of the sodium
chloride solution was added to a small vessel. The vessels containing the samples and the
solution were covered with parafilm and kept inside a CO2 incubator at 37°Celsius to
simulate human body temperature. The samples were removed from incubation at 6 hours
and analyzed using optical microscopy and weight loss measurement. The samples were
removed from the sodium chloride solution and placed in a desiccator for several hours to
undergo dehydration. After the samples were completely dry, they were weighed and
imaged. The samples were then replaced in a new vessel containing 30 ml of fresh SBF
solution and incubated. This process was repeated for 12, 16, and 21hour time points.
3.9 Polymer Coatings for Controlling the Corrosion of Mg Alloys (Phase 2)
3.9.1 Experimental Design and Analysis
The question is posed, “Can direct-write inkjet printing be used as a mechanism
for depositing uniformly distributed protective thin films?” Furthermore, “Can these thin
films aid in retardation of the corrodible magnesium alloy in physiological solutions?”
More specifically, we seek to answer the following questions:
1. Does polymer type and coating thickness have a significant effect on the rate of
metal ion release? (Phase 2a)
2. Does polymer-coating type have a significant effect on the percentage of LDH
activity from Human Bronchial Epithelial Cells? (Phase 2b)
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In Phase 2a, three polymer types (polyetherurethane urea, polycaprolactone, and
poly(lactic-co-glycolic acid) have been identified, each having their own unique
molecular structure and degradation properties. The samples were coated at varying
thicknesses (10 and 20 passes). Thus the independent variables are stated as being the
polymer type (PEUU, PCL, PLGA, Uncoated) and thickness, and the dependent variable
is the metal ion release over time. A 2x3 factorial design was used to assess any
differences among the means of the factor groups as well as the interaction effects
between factors. There were seven experiment conditions and was replicated twice to
asses error. Thus, there was a total of 14 experiment runs. The following null and
alternative hypotheses were formed:
H01 = the sample means for polymer type are equal
H02= the sample means for number of layers are equal
H03 = there is no interaction effect
H11 = at least one of the sample means for polymer type is different
H12= at least one of the sample means for number of layers is different
H13 = an interaction effect is present
A one-way ANOVA was conducted to determine any significant differences
amongst treated coating combinations.

The means of the uncoated samples were

excluded from this analysis. There were six experiment conditions and was replicated
twice to asses error. Thus, there was a total of 12 experiment runs. The following null
and alternative hypotheses were formed:
H0 = the sample means for the coating combinations are equal
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H1= at least one of the sample means for coating combination is different
For phase 2b, a one-way ANOVA was conducted to determine if there are
significant differences between the sample treatment types. In this phase of experiments
each of the treated samples were coated with 20 layers of the various polymer types.
Thus, this experiment contains one factor (i.e. polymer type) and 5 different levels (PCL,
PLGA, PEUU, Uncoated, Cells only) including the low control with no magnesium
exposure. Each of experiment was replicated three times to assess error. Thus, there
were a total of 15 runs. The following null and alternative hypotheses were formed:
H0 = the sample means for polymer type are equal
H1= at least one of the sample means for polymer type is different
The LDH samples also underwent inductively coupled plasma analysis to
determine if there was any correlation between cytotoxicity percentage and magnesium
ion content. The following null and alternative hypotheses were formed:
H0 = the sample means for polymer type are equal
H1= the sample means for number of layers are equal
3.9.2 Experimental Procedure
3.9.2.1 Material Synthesis
Polyetherurethane urea (PEUU) was generously donated by the Wagner Lab at
University of Pittsburgh Institute of Regenerative Medicine and mixed with HFIP to
make a 0.5% w/v solution. Polycaprolactone (PCL), and poly(lactic-co-glycolic acid)
(PLGA) were both donated by the Wake Forrest Institute of Regenerative Medicine. The
PCL arrived as a 10% w/v PCL and dichloromethane (DCM) solution and was further
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diluted with DCM to obtain a 1% w/v solution. A 1% w/v PLGA solution dissolved in
acetone was prepared.
3.9.2.2 Sample Preparation and Coating
5x5 mm coupons of the bulk magnesium alloy were cut and polished. The
coupons were then set into an epoxy resin so that only the top surface of the magnesium
sample was exposed. The surface of the sample was polished again to remove the
magnesium oxide layer. The samples were labeled and imaged using optical microscopy
technique. Samples were stored in a desiccator until it was time for the coating process.
The custom direct-write inkjet setup (Jetlab4 - MicroFab Technologies, Plano, TX)
was used to coat the samples. A 50µm nozzle was used to deposit twenty (20) layers of
the polymer materials named above. A single layer consisted of a progressing back and
forth pattern of continuously deposited droplets as shown in Figure 3.14 (b).

The

samples were then used to conduct two different experiments, in vitro cell compatibility
and immersion test.
3.9.2.3 Immersion Testing
5x5 mm magnesium coupons were cast in epoxy resin as above. Three polymer
types were chosen as coating materials, PEUU, PCL, and PLGA. For each of the
polymer types two samples were coated with ten layers and two were coated with 20
layers. Two samples were left uncoated as a control. The samples were fully immersed
in 2 ml of DMEM + 10% fetal bovine serum + 1% penicillin strip (Figure 3.15).
Aliquots were collected for each of the samples at 6 and 12 hours and then again at 1, 2,
4, 5, 6, 7, and 8 days. At the end of each time point, the old media was collected and
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stored. The vesicle containing the immersed sample was then cleaned and replaced with
fresh media. When the immersion testing process was completed, a 0.5 ml aliquot of
each sample for the various time points was added to 9.5 ml of Tris buffer solution to
achieve a 20 times dilution sample.

Figure 3.15 Depiction of magnesium samples immersed in SBF solution

Figure 3.16 Depiction of inductively coupled plasma equipment
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3.9.2.4 Cell Culture
Normal Human Bronchial Epithelial (NHBE) cells were cultured in complete
media, which consisted of a 50:50 mixture of BEBM/DMEM supplemented with
antibiotics and growth factors. The cells were rapidly thawed from liquid nitrogen in a
37oC water bath and seeded in 6-well culture dishes fitted with rat tail collagen-coated
polycarbonate membrane Transwell® inserts (0.4 µm pore). Complete media (500 mL)
was prepared by combining 250 mL of BEBM and 250 mL of DMEM into a flask with
SingleQuot® components. The cells were fed apically and basolaterally every other day
until they reached 100% confluency (at approximately 7 days). Figure 3.17 (a)-(c) shows
cultured in cells in air-liquid interface at 100% confluency. At that point, an air liquid
interphase (ALI) was established by removing medium from the apical chamber and cells
were fed basolaterally everyday for 14 days to allow full differentiation of the airway
epithelial phenotype. The cells were cultured at 37°Celcius in humidified air and 5%
CO2.

(a)
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(b)

(c)
Figure 3.17 Depiction of healthy normal human bronchial epithelial cells in air
liquid interface
3.9.2.5 Cell – Surface Interface Testing
The Mg samples (n=3 per coating) were coated with 20 layers of polymer and
sterilized under a laminar flow hood with a UV sterilization bulb for 15 minutes on each
side. Each of the samples were then assigned a well number and placed face down such
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that the coated magnesium surface was in direct contact with the epithelial cell layer.
Three wells were labeled as the low control, thus they were cells, which were untreated.
Initial media samples were collected from each well at time zero and stored at -20°C for
lactate dehydrogenase (LDH) assay and elemental analysis via inductively coupled
plasma mass spectrometry (ICP-MS).

Fresh medium was placed in the lower chamber

of each well and the plates were placed in incubation at 37°C and 5% CO2.
Balolateral medium samples were collected again at one hour, four hours, six
hours, 24 hours, and 29 hours. During the sample collection period, 1.5 mL of the
sample media was collected from each of the wells and placed into a small tube. The
tubes were labeled and frozen at -20°C. Any remaining media was aspirated from the
cell well and two mL of fresh media was reapplied to the lower chamber. During this
period, selected wells were imaged by phase contrast microscopy using an Evos xl
inverted microscope (AMG). After the final sample collection, the wells containing the
untreated cells were lysed such that all LDH activity would be released. These samples
were then labeled as the high control and used for LDH analysis.
3.9.2.6 LDH Assay
Following exposure to coated Mg samples, reactions were terminated by
removing materials from the apical surface, collection of basolateral culture medium and
plates were wrapped in foil and stored at -80o C until needed for gene expression analysis.
The Roche cytotoxicity detection kit was used to determine LDH release by the cells at
the indicated time points. This cytotoxicity detection kit measures cytotoxicity and cell
death through the detection of LDH activity which has been released from damaged cells.
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The low control consisted of the untreated cells (n=3) and the high control consisted of
the lysed cells, which provided information about the maximum amount of released LDH
activity in the cells.

The assay was performed according to manufacture’s

recommendation and samples (in triplicate) were transferred into a 96-well plate
according to the template found in Table 3.5 below.
Table 3.5 96 -well sample template for LDH assay

Absorbance measurements were taken for each time point at 492 nm on a
VersaMAX microplate reader (Molecular Devices).

To determine the percentage

cytotoxicity, the average of the triplicates were obtained and the following equation was
applied where exp. is the experimental value (i.e. absorbance value) obtained and high
and low are in regards to the controls, respectively (Equation 1).

Equation 1 Determination of cytotoxicity obtained from LDH absorbance values
3.9.2.7 PCR Analysis
3.9.2.7.1 RNA Extraction
The cell wells were thawed after being preserved at -80° C following the cell
culture experiments. The RNeasy RNA Extraction Kit (Qiagen, Valencia, CA) was
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utilized for RNA extractions according to manufacturer’s instructions. Briefly, to extract
RNA from the NHBE cells 350 µl of RTL buffer was added to each of the 24 wells to
lyse the cells. Using a rubber policeman apparatus, the cells were detached from the
membrane of the wells. Each lysate sample was transferred into a microfuge tube and
vortexed to remove any clumps. Each of the samples were then homogenized by passing
the lysate through 20-gauge (0.9 mm diameter) fitted RNase-free syringe 4-5 times.
Next, 350 µl of 70% EtOH was added and mixed with the lysate by pipetting. The lysate
was then transferred into an RNeasy spin column fitted with a 2 ml collection tube and
spun for 30 seconds at 10,000 rpm, at room temperature. The resulting flow through
from the collection tube was discarded.
The spin column was then transferred into a second collection tube and 350 µl of
RW1 buffer was added. The sample was spun again for 30 seconds at 10,000 rpm. Next,
80 µl of DNase solution was added to the center of the silica-gel membrane in the spin
column and left to incubate at room temperature for 15 minutes. Another 350 µl of RW1
buffer was added to the column and spun at 10,000 rpm for 30 seconds to wash.
The samples were then washed twice by adding 500 µl of buffer RPE onto the
column and spinning for 30 seconds at 10,000 rpm. The samples were then spun at
maximum speed for one minute to dry the columns. RNA was then eluted by transferring
the spin columns into a 1.5 ml microfuge tube and adding 50 µl of RNase-free water
directly to the sample columns. Finally, the samples were spun at 10,000 rpm for one
minute.
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3.9.2.7.2 Determination of RNA concentration and purity
Each of the RNA samples were diluted by adding one part RNA and 49 parts
RNase-free water to obtain a 1/50 dilution. For each sample, 2 µl of diluted RNA was
placed on to the center of a nanoplate reader. The RNA concentration was determined by
measuring the absorption over a UV light at 260 and 280 nm. The purity of RNA was
calculated by determining the ratio A (260/280). The RNA concentration (ng/µl) was
calculated Equation 2.

Equation 2 Determination of RNA concentration
3.9.2.7.3 Complementary DNA (cDNA) Synthesis
Synthesis of cDNA was conducted according to the iScript cDNA Synthesis Kit
(BIO-RAD, Hercules, CA) protocol. A reaction mixture was prepared for a total volume
of 15 µl per sample reaction. Each reaction mixture consisted of 4 components, 4 µl of
5x iScript Reaction Mix, 1 µl of iScript Reverse Transcriptase enzyme, X µl of Nucleasefree water, and X µl of the RNA sample (Table 3.6). The amount of Nuclease-free water
and RNA sample required for each reaction were calculated based on the RNA
concentration per sample. The RNA concentrations and the calculated values for X µl of
Nuclease-free water and X µl of the RNA are shown in Table 3.7 below. Each reaction
mix was spun for 3 seconds and incubated using an iCycler Thermal Cycler (BIO-RAD)
for 5 minutes at 25° C, followed by 30 minutes at 42° C, 5 minutes at 85° C, and finally
cooled at 4° C for at least 5 minutes. Figure 3.18 shows the thermal cycler apparatus.
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Figure 3.18 Depiction of iCycler thermo cycler from BIO-RAD
Table 3.6 Specified amounts for cDNA reaction mixture
Reagent

Amount

5x iScript Reaction Mix
Total RNA Template**
iScript Reverse Transcriptase
Nuclease-free water

4 µl
1 µl
1 µl
q.s. 20 µl

4µl
Refer to Table 3.7
4µl
Refer to Table 3.7

Table 3.7 Calculated RNA and nuclease free water required based on RNA
concentration
Sample
Concentration Desired, µg RNA needed H20 Needed
1
148.2
400
2.70
12.30
2
81.5
400
4.91
10.09
3
71.5
400
5.59
9.41
4
48.5
400
8.25
6.75
5
61.6
400
6.49
8.51
6
92.3
400
4.33
10.67
7
77.7
400
5.15
9.85
8
71.1
400
5.63
9.37
9
112.9
400
3.54
11.46
10
132.9
400
3.01
11.99
11
124
400
3.23
11.77
12
70.3
400
5.69
9.31
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13
14
15
16
17
18
19
20
21
22
23
24

140.3
107.6
59.8
78
64.6
57.1
49.3
58.4
61.7
38.5
34.1
n/a

400
400
400
400
400
400
400
400
400
400
400
n/a

2.85
3.72
6.69
5.13
6.19
7.01
8.11
6.85
6.48
10.39
11.73
n/a

12.15
11.28
8.31
9.87
8.81
7.99
6.89
8.15
8.52
4.61
3.27
n/a

3.9.2.7.4 Measurement of Cyclooxygenase-2 (COX-2) Gene Expression
PCR was used to measure the COX-2 gene expression in NHBE cells exposed to
polymer coated magnesium samples. RNA was extracted and synthesized into cDNA as
described above. COX-2 primer suspended in GoTaq (23 µl) was mixed with 2 µl of the
synthesized cDNA sample. Beta-actin primer suspended in GoTaq (23 µl) was mixed
with the synthesized cDNA sample and used as a reference (Table 3.8). The PCR
protocol was set for an initial 95°C for 4 minutes, followed by 35 cycles at 95°C for 30
seconds, 60°C for 30 seconds and 72°C for 3 minutes. The synthesized cDNA was
separated on 0.8% agarose gel at 80 V for one hour. The gel was then stained for 20
minutes in 0.01% ethidium bromide. The gel was imaged using Biorad Chemi-doc
(Figure 3.19) and Image Lab interface to visualize band density. The densitometry
results were analyzed in order to calculate the relative expression of COX-2 against the
beta actin genes.
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Table 3.8 Synthesis of Cox-2 and beta actin primers

Figure 3.19 Depiction of BIO-RAD chemi-doc
3.9.2.7.5 Statistical Analysis for Cyclooxygenase-2 (COX-2) Gene Expression
The average volume intensity of the beta actin genes was used to obtain
normalized values for the COX-2 expression gene. The normalized values (n=6) were
used to conduct statistical analysis. A one-way analysis of variance was conducted to
determine statistical differences between the mean cyclooxygenase-2 (COX-2) gene
expressions of cells for each experiment type.

After determining the statistical

differences between the experimental means, Tukey’s post hoc analysis was performed to
determine the specific differences between mean pairs.
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CHAPTER 4
RESULTS AND DISCUSSION
4.1 Jetting Optimization
Direct Write Inkjet printing can be employed as a mechanism for depositing nonnewtonian biopolymer fluids to modify the surfaces of surgical implant devices. The
optimal jetting parameters for 0.5% w/v PEUU were obtained by determining the
appropriate frequency, positive/negative jetting voltage, rise time, dwell time, fall time,
and final rise time denoted by f, +V/-V, TR, TD, TF, TFR, respectively, and the reservoir
pressure as described above. These obtained values are approximate values. This is
because of the level of difficulty in obtaining the exact value for the reservoir pressure,
thus the remaining input values needed to be adjusted. The final jetting parameters
obtained at a reservoir pressure of approximately -16 psi were f = 500Hz, +V/-V = 58 V/58 V, TR = 51 µs, TD = 50 µs, TF = 51 µs, and TFR = 51 µs.
4.2 Controlled Release Coatings (Phase 1)
Drug release kinetics and surface morphology and thickness were analyzed to
evaluate the possible factors that might affect the release behaviors of the multilayer
coatings. The factors of interest included: (1) polymer concentration, (2) drug loading and
(3) the number of overprint passes.
4.2.1 Characterization of Release
The measured release kinetics profiles represent an accelerated curve with respect
to time. Thus, samples under in vivo conditions would release over a longer period of
time than those observed here. Figure 4.1 shows the release profiles for samples with
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varying polymer, drug (taxol) and number of overprint passes as tabulated in Table 4.1.
The nomenclature (1-5-10P-S2) corresponds to 1% PEUU, 5% taxol, 10 Passes, Sample
2. Samples with smaller film thickness and lower drug loadings resulted in longer and
steady rates of drug release. While, samples with higher drug loadings resulted in a high
percentage of release during the initial burst release period. This situation was attributed
to the burst release of crystallized taxol particles (beads) within the polymer matrix.
Figure 4.2 (a) and (b) shows the (a) top view and (b) side view of the taxol beads with
average diameters of 5 to 8 microns. These beads are a result of reaching the saturation
limit of the taxol within the biopolymer solution and they indicate the upper limit for
possible drug amount to be loaded.
Table 4.1 Factor levels for multilayered controlled release coatings
No.
Factor
Low level
High level
1
Polymer concentration (%w/v)
1
1.5
2
(Drug) paclitaxel concentration 5
10
(%w/w)
3
Number of overprint passes
10
20
The higher polymer concentrations and film thicknesses (20 passes) resulted in an
early dislodgement of the polymer thin film. This situation was due to the lack of
adhesion between the polymer and the titanium substrate. Release readings were
discontinued after partial dislodgement of these coatings after day 5 to eliminate
erroneous data. However, the dislodged coatings released approximately double the taxol
based on the higher surface area of exposure to the DPBS as compared to the adhered
coatings. (Nomenclature: 1-5-10P-S2 stands to 1% PEUU, 5% taxol, 10 Passes, Sample
2)
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Figure 4.1 Phase 1 taxol release profiles for determining candidate experiment types

(a)
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(b)
Figure 4.2 (a) Top view (b) Side view of crystallized taxol particles precipitated from
polymer matrix
4.2.2 Surface morphology and film thickness evaluation
The surface morphology and film thickness of the drug loaded polymeric coatings
were evaluated using scanning electron microscopy and the optical profilometer,
respectively. The polymer film was cut to reveal the cross-section areas and thickness
profiles. Figure 4.3 shows the (a) top view and (b) cross-section view of the polymer film
with 10 passes of coatings. As can be seen from the top and cross-section views, there are
whiskers of polymer that adhered to the Ti substrate for the lower number of passes (10).
The average thickness for a 20-pass film obtained from the optical profilometer testing
varied between 18 to 22 microns. However, the thickness obtained from the SEM
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measurements was around 20 microns in thickness. The approximate coating thickness
for each print pass was around 1 micron in thickness.

(a)

(b)
Figure 4.3 (a) Top view (b) cross-section of drug loaded polymer film on Ti
substrate
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4.3 Controlled Release Coatings (Phase 2)
4.3.1 Characterization of Release
The two factors studied were taxol concentration and the number of layers. The
levels of taxol concentration were 5% and 10% w/v and the two levels of layer thickness
were 10 and 20 layers. Thus, there was a total of four experiment types (5% taxol and 10
layers, 10% taxol and 10 layers, 5% taxol and 20 layers, 10% taxol and 20 layers). The
absorbance values obtained from the spectrophotometer were compared to the values of
the standard curve and the final concentration (µg/ml) of taxol present in the samples was
derived. The average concentration of taxol present in the samples having 10 layers and
containing 5% and 10% w/w of the polymer content was 26.07 µg/ml and 49.09 µg/ml,
respectively. For the samples coated with 20 layers and containing 5% and 10% w/w of
taxol, the final concentrations were 31. 29 µg/ml and 83.19 µg/ml, respectively. This
condition is depicted in Figure 4.4.
The experimental data were assessed to ensure that the assumptions of normality
and randomness were satisfied. It was determined that the data were normally distributed
and did not exhibit any obvious trends or patterns; thus the data was, in fact, random in
nature. A depiction of the normality and randomness of the data sets can be found in
figures 4.5a and 4.5b, respectively. The statistical relevance of the independent variables
on the total taxol concentration after 21 days was thus suitable for the application of
analysis of Variance (i.e. ANOVA) statistical testing.
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Figure 4.4 Taxol concentration release profile for 21-day period

(a)
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(b)
Figure 4.5 (a) Normality plot (b) randomness plot for taxol release data
A 2x2 factorial design was conducted to determine the main effects of the given
factors on the total drug concentration released at the end of the sample collection period
(i.e. 21 days). The findings showed that the variations in drug dosage and number of
layers had strikingly significant effects (p = 0.00) on the total drug concentration released
at p < 0.05. More specifically, the difference in data means for an increasing drug loading
percentage was approximately 50 µg/ml and nearly 40 µg/ml for increasing the number
of coating layers (Figure 4.6a). The interaction plot from the DOE analysis showed that
the combined factors were also significant (p = 0.00) with regards to the drug release
concentration at the end of the 21 days (Figure 4.6b). Details of the statistical output
analysis can be found in Appendix A. The difference in data means for the samples
having 5% w/w drug dosage showed a slight increase (approx. 10 µg/ml) as the number
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of passes increased from 10 to 20 layers. Samples having 10% w/w drug dosage showed
a more profound increase (approximately 60 µg/ml) among data means as the number of
layers increased from 10 to 20 layers.
The percentage of drug released at the various time points was also obtained. It
was evident that the burst period for each of the sample categories fell between t = 0 and t
= 24 hours (i.e. after 24 hours the percentage of drug reached a steady state of release).
Thus the percentage of the total drug released after 24 hours for the samples containing
5% and 10% w/w and 10 layers was 60.60% and 61.33%, respectively. For samples
containing 5% and 10% w/w having 20 layers, the percentage of total drug release was
51.69% and 49.37%. It appeared that the samples, which contained the thinner coatings,
had a more profound initial burst period. The samples having the thicker layer of
coatings appeared to have a steadier rate of release during the initial burst period.
However, a test of statistical significance was required to determine any real differences
(Figures 4.7 a-d).

(a)
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(b)
Figure 4.6 (a) Main affect and (b) interaction plot for total drug release after 21
days

(a)
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(b)

(c)
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(d)
Figure 4.7 Percentage of total drug release over time for (a) 5 % taxol and 10 passes
(b) 10 % taxol and 10 passes (c) 5 % taxol and 20 passes (d) 10 % taxol and 20
passes
The experimental data were assessed to ensure that the assumptions of normality
and randomness were satisfied. It was determined that the data were normally distributed
and did not exhibit any obvious trends or patterns. Therefore the data was random in
nature. A depiction of the normality and randomness data is shown in figure 4.8 (a) and
4.8 (b), respectively. As a result, the statistical relevance of the independent variables on
the percentage burst release was suitable for the application of analysis of Variance (i.e.
ANOVA) statistical testing.
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(b)

(b)
Figure 4.8 (a) Normality plot and (b) randomness plot for percentage burst release.
A 2x2 factorial design was conducted to determine the main effects of the given
factors on the percentage of drug released during the burst period. The burst period
identified for analysis was between 0 and 24 hours. The results showed that for both
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factors (drug concentration and number of passes) there was a strikingly significant effect
(p = 0.00) on the drug released during the burst phase at p < 0.05. Therefore, the null
hypothesis was rejected. More specifically, by increasing the drug concentration from
5% w/w to 10% w/w a visibly higher difference in the data means was realized.
Although increasing the number of layers from 10 to 20 showed a relatively lower
difference in data means, the differences were still significant (Figure 4.9a).

The

statistical output pertaining to the main and interaction effects on burst release percentage
can be found in Appendix A.
Interactions between the two factors also had significant effects (p = 0.00) on the
burst release percentage. Thus any combination of the factors tested could be employed
to achieve the desired drug release behaviors during the initial release period. Results
showed that for the samples containing 5% w/w of drug loading, the data means showed
a marginal decrease in the percentages the drug released during the burst period as the
number of layers was increased from 10 to 20. For the samples with a 10% w/w drug
loading, the samples showed a significant increase in the percentage drug release during
the burst period as the number of layers was increased from 10 to 20 (Figure 4.9b).
4.3.2 Blood Collection and Compatibility Test
SEM micrographs taken at 500X and 2,000X show that evenly distributed clusters
of platelets have attached to only the sample control surfaces containing PEUU only.
Micrographs were also obtained for the samples containing 5% and 10% w/w of the taxol
drug. One can visually see the decrease in adhering platelets as the taxol concentration is
increased.
104

(a)

(b)
Figure 4.9 (a) Main and (b) interaction affects plot for percentage of total drug
released during the burst release period
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Platelet deposition onto the sample surfaces was determined by LDH assay.
Samples containing PEUU with no taxol drug were fabricated as a control (Figures 4.11a
and b). The data was presented as means with standard deviation. The average number
of platelets was 10,191 cells/mm2 with a standard deviation of 1,194. The sample with
PEUU containing 5% taxol visually showed a decrease in platelet deposition compared to
the control and the sample containing 10% taxol showed more sparse platelet deposition
compared to the control (Figure 4.12-4.13a and b). The average platelet count with
standard deviations for the 5% and 10% sample were 4,637 cells/mm2 (1,339) and 3,933
cells/mm2 (3,933), respectively.

Figure 4.10 Statistical significance of drug concentration of blood platelet deposition
The statistical significance among sample groups was determined using One-way
Analysis of Variance (ANOVA). Post-hoc Newman-Keuls testing was performed to
determine specific differences. Statistical significance among the samples containing
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only PEUU (control) and both sets of samples containing 5% and 10% taxol embedded in
PEUU were found to exists at p < 0.05. Thus, the p- value to determine statistical
significance between the control and the sample containing 5% taxol was 0.016376. This
value is below 0.05. Therefore, the addition of a 5% w/w taxol drug loading had a
statistically significant effect on platelet adhesion. The resulting p-value to determine
statistical significance between the control and the sample containing 10% was 0.022789
(Figure 4.10). This value was also lower than the standard p < 0.05. Thus, the addition
of a 10% w/v taxol concentration also had a significant effect on platelet adhesion (Table
4.2). The results also showed that the difference between the additions of 5% taxol
versus the addition of 10% taxol was insignificant.
Table 4.2 Specific significance between groups for blood platelet deposition

4.3.3 Inhibition of Rat Smooth Muscle Cells
The metabolic means of samples containing 10 and 20 layers with a 5% w/v drug
loading were compared to the metabolic means of samples having 10 and 20 layers of
PEUU with no drug, respectively.

In addition, the metabolic means of samples

containing 10 and 20 layers with a 10% w/v drug loading were compared to the
metabolic means of samples having 10 and 20 layers of PEUU with no drug respectively.
Lastly, the metabolic means of each of the experiment groups were compared with the
mean metabolic index of cells cultured on Tissue Culture Polystyrene (TCPS).
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(a)

(b)
Figure 4.11 Platelet deposition for control, PEUU with no drug loading (a) 500x (b)
2,000x

108

(a)

(b)
Figure 4.12 Platelet deposition on PEUU coating with 5% taxol concentration (a)
500x (b) 2,000x
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(a)

(b)
Figure 4.13 Platelet deposition on PEUU with 10% drug loading (a) 500x (b) 2,000x
The TCPS materials were used in the cell culture to encourage cell proliferation
across the substrate. Thus, the metabolic index here is the natural metabolic index from
cells as they were cultured over a 1, 4, and 7 day period. As compared to the cells
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cultured on bare titanium substrate there was a slight increase in metabolic index. The
TCPS samples were also compared to samples coated with 10 and 20 passes of PEUU
without any drug loading and results showed an even further increase in metabolic
activity for the 20 layer coatings. This fact indicates that there was an increase in cell
count where a 20-layer coating was present, which means that the cells can adapt to the
polymer coating itself. A description of this situation is shown in Figure 4.14.

Figure 4.14 Statistical significance of controlled release experiment types on cell
inhibition
In this research, it was hypothesized that taxol-loaded PEUU coatings would be
used to inhibit cell proliferation of undesired cancer cells based on increased coating
material and drug dosage. The results showed that there was a statistically significant
difference between the control groups (i.e. TCPS, bare Ti, 10 layers of PEUU, and 20
layers of PEUU) when compared to each of the respective experiment groups. For
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example, after 4 and 7 days there was a significant decrease in metabolic activity when
5% and 10% w/w of taxol were added to 10 layers of PEUU. The same finding is true
when 5% and 10% w/w of taxol was added to 20 layers of PEUU. However, there does
not appear to be a significant difference between the various experimental groups.
We proposed that the direct-write technique could be used to deposit a variety of
other non-newtonian biopolymer fluids encompassing a variety of therapeutic agent for
drug delivery. However, studies must be conducted to study the release profile of a given
agent from a given polymer coating type.
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CHAPTER 5
RESULTS AND DISCUSSION
5.1 Jetting Optimization
The direct-write inkjet technique was used to deposit non-newtonian biopolymer
fluids for controlling the corrosion of magnesium alloys. The optimal jetting parameters
were obtained by determining the appropriate frequency; the positive/negative jetting
voltage, rise time, dwell time, fall time, and final rise time denoted by f, +V/-V, TR, TD,
TF, TFR, respectively, and reservoir pressure. These obtained values are approximate
values. This is because of the level of difficulty in obtaining the exact value for the
reservoir pressure. Thus the remaining input values needed to be adjusted. The final
jetting parameters obtained for PEUU at a reservoir pressure of approximately -16 psi
were f = 500Hz, +V/-V = 58 V/-58 V, TR = 51 µs, TD = 50 µs, TF = 51 µs, and TFR = 51
µs. For PCL, the final jetting parameters obtained at a reservoir pressure between -8 psi
and -12 psi were f = 500Hz, +V/-V = 42 V/-42 V, TR = 22 µs, TD = 25 µs, TF = 38 µs,
and TFR = 22 µs. For PLGA, the final jetting parameters obtained at a reservoir pressure
between -8 psi and -12 psi were f = 500Hz, +V/-V = 32 V/-32 V, TR = 22 µs, TD = 32 µs,
TF = 24 µs, and TFR = 22 µs.
5.2 Polymer Coatings for Controlling the Corrosion of Mg Alloys (Phase 1)
Immersion testing was terminated at 21 hours, as the bare Mg alloy surface
showed severe pitting and corrosion, thus was defunct for implantable conditions. It is
important to note that the corrosion conditions for samples are at an accelerated pace as
compared to the actual implant conditions. This situation occurs because implants are in
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prominent contact with tissue and bone structures with relatively lower liquid interface
from the site blood vessels. In contrast, the tests were conducted in complete liquid
immersion to simulate longer durations in actual implant conditions.

Cumulative Weight Loss/Gain
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Figure 5.1 Cyclic corrosion mechanism in magnesium alloy samples
5.2.1 Cyclic Corrosion Mechanism in Mg Alloy Samples
In a typical corrosion reaction, the Mg alloy reacts with water leading to
magnesium hydroxide and the release of hydrogen gas. This process is shown in Equation
(3). The uncoated magnesium sample showed a cyclic corrosion mechanism as seen in
figure 5.1. During the initial six hours exposed magnesium alloy surface underwent
corrosion with the formation of magnesium hydroxide Mg(OH)2 products on the surface.
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Equation 3 Chemical reaction for magnesium hydroxide
The corrosion products resulted in an increase in the weight of the sample.
Further, at 12hrs duration the corrosion products detached from the underlying sample
into the SBF resulting in weight loss of the sample. The freshly exposed surface of the
sample underwent subsequent corrosion and formation of Mg(OH)2 products at 16hrs.
Finally, at 21hrs these corrosion products detached resulting in severe pitting and
degradation of the underlying sample as seen in Figure 5.2 (right). Though, the bare
sample has incremental weight gains during corrosion, it is evident from the Figure 5.1
that the overall trend is downward (weight loss) indicating cumulative weight loss of Mg
alloy.
The PLGA based polymeric coating with 100-micron deposition spacing shows
weight loss at 6 and 12 hours, respectively. This fact was attributed to the degradation of
the PLGA coating during the initial period. The larger spacing of the deposited
microdroplets formed a porous coating allowing media to infiltrate within the layers. At
16hrs the PLGA-100 coating shows weight gain due to the formation of corrosion
products within the film when in contact with the entrapped media. Further, at 21hrs a
particular region within the coating film detaches (Figure 5.3) allowing the corrosion
products to escape. Thisprocess results in a weight loss from the PLGA-100 sample.
The PLGA-50 sample with tighter deposition pattern showed lower weight loss
and corrosion behavior as compared to the PLGA-100 coating. This fact is due to PLGA-
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50 coating is less porous and offers resistance to media infiltration. During the initial
12hr period, there was weight loss due to the degradation of the PLGA film. Further, at
16hrs corrosion products are formed within the PLGA-50 film at specific locations
resulting in weight gain. This process is followed by a release of Mg alloy degradation
product through the porous sections of the PLGA-50 film (Figure 5.4) at 21hrs and
subsequent weight loss.
PCL (Polycaprolactone) is a tough biodegradable polymer with enhanced
mechanical properties and chemical stability as compared to PLGA. Similar trends of
initial weight loss (12hrs) due to polymer degradation were observed with the PCL-50
coating. This process was followed by Mg alloy degradation and weight gain as shown in
Figure 5.1. Finally, at 21hrs duration, the degradation products were released to the
media resulting in weight loss. It is important to note that the corrosion mechanism for
PCL-50 is analogous to PLGA-50 the overall weight loss was lower in the former case.
This is due to the enhanced film stability of PCL-50 as shown in Figure 5.5.

Figure 5.2 Uncoated magnesium alloy (left) before t=0 and (right) after t=21 hours
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Figure 5.3 PLGA-100 Mg alloy (left) t=0 and (right) t=21 hours

Figure 5.4 PLGA-50 Mg alloy (left) t=0 and (right) t=21 hours
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Figure 5.5 PCL-50 Mg alloy (left) t=0 and (right) t=21 hours

Figure 5.6 PCL-100 Mg alloy (left) t=0 and (right) t=21 hours
The PCL-100 coating had higher porosity and resulted in media infiltration during
the initial 6hr period. However, because the PCL film has better adhesion properties to
the Mg substrate, the corrosion products were retained within leading to a weight gain.
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During the next 10hrs (6 to 16hrs) there was weight loss due to PCL degradation and the
release of corrosion products through the porous film. This situation led to exposure of
the underlying Mg alloy surface to fresh media resulting in corrosion products (Figure 5.6
right) and subsequent weight gain at 21hrs.
5.2.2 Total Weight Loss/Gain in Mg Alloy Samples

Total Weight Loss/Gain

Total Weight Loss/Gain, mg

8
6
4
2
0
Bare

PLGA‐100

PLGA‐50

PCL‐50

PCL‐100

‐2
‐4

Sample Type

Figure 5.7 Weight loss/gain of various sample types
It is important to note the caveat that the polymeric coatings show higher weight
loss as compared to bare Mg alloy. This situation is attributed to the combination of the
weight loss of the polymer and Mg corrosion products, with the former being a
significant proportion of the total weight loss. As can be seen from Figure 8 the sample
PLGA-100 has the highest weight loss due to high corrosion rate and degradation of
porous PLGA film. PLGA-50 and PCL-50 show comparable weight loss due to lower
corrosion rates. PCL-100 shows weight gain at 21 hrs due to the retention of corrosion
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products within the PCL film. It is important to note, that corrosion cycles for different
samples may not coincide at the same time point. For example, PLGA is a fast degrading
polymer and may gain and lose weight at frequent intervals as compared to PCL.
5.2.3 Corrosion Metrics Based on Polymer Type and Pitch Distance
Table 5.1 Corrosion impeding properties of polymer coatings
Polymer Type
Degradation Properties
PCL
PLGA

Tough biodegradable polyester with slower
dissolution characteristics
Tunable degradation rates based on the
adjustable chemical composition of lactic and
glycolic acids within polymer

Table 5.2 Relationship between pitch distance and corrosion rate
Pitch Distance
Porosity
50
100

Dense polymer microstructure with close
overlap
Lower overlap and presence of permeable
polymer layers

Corrosion
Rate of Mg
alloy
Low
High

Corrosion
Rate of Mg
alloy
Low
High

Table 5.1 shows differences in the corrosion behavior of the Mg alloy surface
based on the polymer type. PCL serves as a more robust polymer to protect the
underlying Mg alloy surface from corrosion as compared to PLGA. However, the PLGA
polymer may have tunable degradation rates, which are obtained by varying the ratio of
lactic and glycolic acids within the polymer. Thus, depending on the application intent,
one can employ either of these polymers to obtain controlled corrosion behavior. Table
5.2 shows the relationship between pitch distance (interspacing of deposited polymer
microdroplets on substrate) and the corrosion rate of the Mg alloy surface. As shown in
120

Table 5.2, larger pitch distances (100µm) lead to porous polymer layers resulting in
infiltration of the biological media to the Mg alloy surface. Thus, higher corrosion
products are formed at this pitch distance for both the polymer types. On the contrary,
tighter pitch distances (50µm) form dense and homogeneous polymer microstructures
prolonging the life of the polymer coatings and lowering the corrosion of the underlying
Mg alloy surface. These metrics play an important role in determining the choice of
polymer type and pitch distance to control Mg alloy corrosion for specific implant
applications.
5.3 Polymer Coatings for Controlling the Corrosion of Mg Alloys (Phase 2)
5.3.1 Immersion Testing (ICP)
The samples were immersed in simulated body fluid (SBF) to initiate the
corrosion process. Sample aliquots taken at each of the specified time points were then
tested for magnesium ion presence by inductively coupled plasma (ICP) elemental
analysis. The immersion test was stopped after 8 days due to peeling of the polymeric
coating. The effect that coating thickness (10 versus 20 layers) had on magnesium ion
presence was compared among all polymer types. For example, a comparison between
10 layers of PEUU and 20 layers of PEUU was made to determine the effects of layer
thickness for this polymer type on the magnesium presence.
For the PEUU sample coated with 10 and 20 layers, 0.0010 mol/L and 0.0028
mol/L of magnesium was present in the SBF solution, respectively (Figure 5.9). Samples
coated with 10 and 20 layers of PLGA showed a 0.004 mol/L and 0.0016 mol/L
magnesium presence in SBF, respectively (Figure 5.10). For the PCL sample coated with
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10 and 20 layers, 0.0026 mol/L and 0.0059 mol/L of magnesium was present in the SBF
solution, respectively (Figure 5.8). Therefore, it is shown that coating thickness does
have some effect on magnesium presence. However statistical analysis was necessary to
determine if the differences were significant.
It is apparent through the data analysis that for the PCL coating, an increase in the
polymer material resulted in an adverse effect on the magnesium ion content that was
ultimately released into the SBF solution after the 8-day immersion period (Figure 5.8).
This phenomenon is explained because of the materials tendency to adhere to the surface
of the magnesium alloy. Thus, maintaining any fluid and corrosion byproduct that may
have seeped through the polymer coating.

The fluid entrapped within the polymer

coating causes increased corrosion of the magnesium alloy material.

Figure 5.8 Magnesium content comparison of layer thickness for PCL coating
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Figure 5.9 Magnesium content comparison of layer thickness for PEUU coating

Figure 5.10 Magnesium content comparison of layer thickness for PLGA coating
A comparison between the uncoated magnesium sample and the samples coated
with 10 layers of each polymer type was noted after an 8-day immersion period. For the
uncoated sample, the amount of magnesium present in the SBF solution was 0.0078
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mol/L. For the coated samples, both PCL and PEUU offered the best protective coatings
having 0.0026 mol/L and 0.0028 mol/L magnesium presences respectively. The PLGA
coating was shown to be the least protective coating with 0.0040 mol/L.
A comparison between the uncoated magnesium sample and the samples coated
with 20 layers of each polymer type was also noted. This is shown in figure 5.11. For
the uncoated sample the amount of magnesium present in the SBF solution was 0.0078
mol/L. For the coated samples, PEUU offered the best protective coating and a more
consistent rate of corrosion having 0.0010 mol/L mg presences. The PLGA coating was
also found to be a good protective coating with 0.0016 mol/L. The corrosion rate of the
PCL coating was more comparable to that of the uncoated sample. It was evident that
varying the levels of each of the identified factors did have some effect on the
magnesium content present in the SBF solution, however statistical analysis was
necessary to determine tany significant differences.

Figure 5.11 Magnesium content comparison between all treatment types
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The experimental data were assessed to ensure that the assumptions of normality
and randomness were satisfied. It was determined that the data were normally distributed
and did not exhibit any obvious trends or patterns, thus the data was, in fact, random in
nature. The normality and randomness plots for data comparing the polymer coating
types amongst each other are depicted in figures 12a and 12b, respectively. As a result,
the statistical relevance of the independent variables on magnesium ion content was
suitable for the application of analysis of Variance (i.e. ANOVA) statistical testing.
A 3x2 factorial analysis was conducted to compare the effects of the polymer type
and number of printed layers on the magnesium ion presence after the 8-day immersion
period. Therefore, the uncoated samples were omitted from this analysis. The results of
the analysis revealed that there is no actual significant effect amongst the polymer
coating types. However, the main effects plot is consistent with the results, which shows
that between the three coating types differences do exists although they may not be
significant (Figure 5.13a). Here again, it is shown that PEUU offers the best protective
coating followed by PLGA and PCL.
The interaction plot reveals also that increasing the number of layers of PLGA
and PEUU offers better corrosion protection whereas increasing the number of PCL
layers from 10 to 20 results in an increase in corrosion byproduct when fully immersed in
the SBF solution (Figure 5.13b). For matching magnesium degradation to bone growth
or repair, PCL should be eliminated as a possible surface coating material, as it does not
significantly reduce the rate of corrosion. Details of the factorial design for magnesium
ion content are shown in Appendix C.
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(a)

(b)
Figure 5.12 (a) Normality plot and (b) Randomness plot for data comparison
amongst polymer coating types
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(a)

(b)
Figure 5.13 (a) Main and (b) interaction affect plots for polymer type and layer
thickness amongst polymer coating types
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The experimental data were assessed to ensure the assumptions of normality and
randomness were satisfied. It was determined that the data were normally distributed and
did not exhibit any obvious trends or patterns, thus the data was, in fact, random in
nature. Normality and Randomness for data comparisons between all sample treatment
types were validated and can be found in figures 5.14a and b, respectively. As a result,
the statistical relevance of the independent variables on magnesium ion content was,
again, suitable for the application of analysis of Variance (i.e. ANOVA) statistical
testing.
A One-way ANOVA was conducted to compare each experiment type against the
control (uncoated) for statistical significance. The results of this analysis showed that
there was a statistical difference between at least two of the sample means given p =
0.036 which is less than the specified alpha level of 0.05 (Appendix C). A Tukey’s post
hoc analysis was conducted to determine exactly which of the data means were
statistically different. A depiction of the differences between the data means is shown in
figure 5.15. The result from the Tukey analysis showed that the difference in the data
mean for the uncoated samples was statistically different from the mean samples coated
with 20 passes of PEUU. This finding was consistent wit the hypothesis that the PEUU
coating would provide the most corrosion protection for the magnesium alloy. This
coating could be applied for controlled release of magnesium for cardiovascular and
tracheal stent applications. There was no significant affect on the magnesium content for
all other experiment categories.
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(a)

(b)
Figure 5.14 (a) Normality plot and (b) randomness plot for data comparison of all
samples types
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(b)
Figure 5.15 Box plot for ICP data depicting differences in data means
5.3.2 Biocompatibility of Polymer Coated Magnesium Alloys
LDH activity was assessed as previously described. Due to the variation between
the cultured cells in each well, the cytotoxicity levels from the LDH assays were
converted to percentage of the high control values. This was so that each of the samples
could be compared to the total possible LDH activity. The treated samples were also
compared to the percentage LDH activity of the low control samples, which saw no
exposure to the magnesium alloy.
LDH activity was collected over the course of a 24 hour period at t = 0, 1, 4, 6,
and 24 hours. The sample data collected at time zero represents two distinct events. The
first was that this sample was collected at the end of a 24-hour period prior to initiation of
the experiment. This was to gauge LDH release over a one-day period. This is apparent
in the graph shown below which depicts a sample reading that shows significantly higher
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LDH activity when compared to subsequent readings. Also, at time zero fresh media was
added to each of the sample wells to initiate the new testing period. Thus, it is taken that
each time point represents the end of a sample collection period.
First it is necessary to describe the pattern of LDH activity of the low control
samples (i.e. samples unexposed to the magnesium alloy). From t = 0 to t = 1 hour, an
apparent decrease in LDH activity was observed. During the one-hour period the cells
seemed to be undisturbed thus not much LDH release had occurred. At t = 4 the media
captured LDH activity for a slightly longer time period (i.e. three hours) and as a result
slightly higher levels of LDH activity was recorded. After 24 hours, the cell media
collected LDH activity for 18 hours thus there is a large spike in LDH activity. It is
important to note that the cultured NHBE cells were cultured for 23 days, which included
conversion into air liquid interface. Thus, the cells were expected to show some signs of
stress irrespective of magnesium exposure around 24 hours after reaching confluency.
For the cultured wells containing the various treated sample types, results show
that between t = 1 hour and t = 6 hours the cells seem to be responding in a similar
manner irrespective of the treatment type. However, the cultures containing polymer
coated samples showed decreasing LDH activity as compared to the samples containing
no magnesium exposure (cells only), which showed increases in LDH release. This is an
indication that the cells are responding positively to magnesium exposure. At the next
sample collection, t = 24 hours, all of the well containing the various treated samples
show an increase in LDH release. The data analysis was cut of at the 24-hour time period
due to the naturally declining health of the cells in air-liquid interface.
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Also, the

difference of time between the 24-hour time point and the 29-hour time point was not
enough time to collect relevant amounts of LDH activity. A depiction of LDH activity
collected for each time point is shown in figure 5.16.
The cells, which were exposed to the uncoated magnesium surface, showed the
least amount of LDH activity. To explain this phenomenon, one could say that more
magnesium exposure contributed positively to the overall health of the cells. In addition,
it could be said that a given polymer type is more compatible than others when placed in
the physiological environment. However, further testing to study the cell activity at the
various time points was required.
Although the results showed varying levels of LDH release, cytotoxicity levels
had not reached a toxic range (i.e. > 30%) after 24 hours of exposure (Figure 5.17a). For
LDH activity over a 24-hour period, cytotoxicity levels were expected to increase slightly
over time due to the natural death process. However, at the end of the 24-hour period, the
greatest difference existed between the cells only (i.e. low control) and the uncoated
magnesium alloy cultures (Figure 5.17b). This indicates that any apparent toxicity that
was present in the cultures was unlikely due to the polymer coating materials. These
findings seem to be consistent with the results from the ICP tests in which it was
concluded that there were no significant differences between polymer coating materials.
However, an analysis of statistical significance for percentage LDH activity among the
treatment types was necessary.
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Figure 5.16 Depiction of fluctuating LDH activity for all time points
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(a)

(b)
Figure 5.17 (a) Depiction of trends in LDH activity over 24 hours (b) increasing
LDH activity over 24 hours
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The experimental data were assessed to ensure the assumptions of normality and
randomness were satisfied. It was determined that the data were normally distributed and
did not exhibit any obvious trends or patterns, thus the data was, in fact, random in
nature. A depiction of the normality and randomness plots for the LDH data set is shown
in figure 5.18a and b, respectively.

As a result, the statistical relevance of the

independent variables on percentage LDH activity after 24 hours was suitable for the
application of analysis of Variance (i.e. ANOVA) statistical tests.
A one-way analysis of variance was conducted on the percentages of LDH
activity after a 24-hour period. The differences between the mean LDH release for each
sample treatment type are depicted in figure 5.19. The results showed that significant
differences between at least one of the means for LDH release were present given p =
0.041, amongst the experiment groups at p < 0.05 (Appendix D). Therefore it was
necessary to reject the null hypothesis that there were no significant differences between
the means of the identified experiment groups.
A follow-up post hoc analysis was performed to determine specific differences.
Findings from the Tukey’s post hoc analysis showed that there were significant
differences between the low control (cells only) samples and the uncoated samples. It is
important to note that the results of this analysis confirm also that the presence of
magnesium does show that the LDH activity decreases significantly following
magnesium exposure. Differences between all other experiment groups were found to be
insignificant. Thus, these findings are consistent with the results from the immersion
tests.
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(a)

(b)
Figure 5.18 (a) Normality plot and (b) randomness plot for LDH data collection set
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Figure 5.19 Box plot for LDH data depicting differences in data means
The samples from the LDH release experiment were preserved so that the
magnesium ion content of the sample media collected could also be measured. The
experimental data were assessed to ensure the assumptions of normality and randomness
were satisfied. It was determined that the data were normally distributed and did not
exhibit any obvious trends or patterns, thus the data was, in fact, random in nature. The
normality and randomness data plot for magnesium content in the LDH samples are
shown in figures 5.20a and b, respectively. As a result, the statistical relevance of the
independent variables on magnesium ion content in the LDH samples was, again, suitable
for the application of analysis of Variance (i.e. ANOVA) statistical testing.
A one-way ANOVA was also conducted on the magnesium content present
within the samples cell wells to determine if there was a difference of means between at
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least two of the experiment groups. The results of this analysis confirmed that there were
highly significant differences given p = 0.005, between at least two of the groups at p <
0.05 (Appendix D).

The differences between mean magnesium content for the LDH

sample treatment types are depicted in figure 5.21. Here again, the null hypothesis was
rejected and Tukey’s post hoc analysis was conducted to determine specific differences.
The results showed that the difference in means between the low control (cell
only) and the uncoated samples was significant. There was also a significant difference
between the low control and the samples containing the PCL coating. Lastly, statistical
differences were found between the samples containing the PEUU coating and both the
uncoated and PCL coated samples. This is also consistent with the ICP results from the
immersion test in which both the uncoated and PCL coated samples displayed similar
corrosion behaviors. Also, from the immersion test, the PEUU coated samples released
the lowest magnesium ion content, which is shown here to be comparable to the low
control.

Therefore, the statistical differences occur between the groups that were

expected from the ICP results to have the highest and lowest magnesium content. In the
following section we conduct a PCR analysis to determine if whether the LDH release is
a result of the polymer coating type or increases in magnesium content.
Here again, these results confirm that although, PCL seems to offer the least
protection from corrosion, the cells showed a positive reaction to the increased exposure
to the magnesium. This again indicates that controlled magnesium exposure promotes
good health in airway cells.
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(a)

(b)
Figure 5.20 (a) Normality plot and (b) randomness plot for LDH data
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Figure 5.21 Box plot for LDH data depicting differences in data means
5.3.3 PCR Analysis
A polymerase chain reaction (PCR) analysis was performed to measure the Cox-2
gene expression in NHBE cells exposed to different sample conditions. The Cox-2 gene
expression is indicative of the inflammatory response of the cells. This analysis was an
end point analysis that allowed us to understand the health of the cells at the end of 29
hours. The corrosion of magnesium alloy samples resulted in release of magnesium ions
within the media. The presence of magnesium ions within the media was measured using
the ICP analysis. Thus, depending on their presence, it was hypothesized that higher
magnesium ions resulted in higher Cox-2 gene expression based on the cell distress.
The PCR results for the different samples were labeled below as follows, 1-6
PCL, 7-12 PLGA, 13-18 PEUU, 19-21 Uncoated, 22-23 Cells only. The PCR for both
Beta Actin and COX-2 were analyzed where Beta Actin was used as an internal control.
140

The average intensity of 6 bands was used to normalize the Cox-2 data sets. Base pair
150 was used to analyze intensity of Cox-2. The PCR image was inverted to measure
darker intensities at base pair 150 for the different sample groups noted above. The
darkness intensities were integrated to obtain volumetric intensities for further statistical
analysis.

Figure 5.22 Normalized Cox-2 gene expression
The higher Cox-2 gene expression in both uncoated (bare) and PCL polymer
coating, shown in Figure 5.22, is due to the corresponding higher presence of magnesium
ions within the media. The PCL polymer coating resulted in the formation of pockets that
entrap media leading to higher corrosion rates. The two polymers PLGA and PEUU
offered higher protection to the underlying Mg alloy surface resulting in lower
magnesium ion release and corresponding Cox-2 gene expression. The Cox-2 gene
expression values for PEUU and PLGA are comparable to those of natural cells (low
control). These results seemed to be consistent with the magnesium ion content within
media for different sample types as explained previous sections. However, test for
statistical differences was necessary.
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The experimental data were assessed to ensure the assumptions of normality and
randomness were satisfied. It was determined that the data were normally distributed and
did not exhibit any obvious trends or patterns, thus the data was, in fact, random in
nature. As a result, the statistical relevance of the independent variables on Cox-2 gene
expression was suitable for the application of analysis of Variance (i.e. ANOVA)
statistical testing.
A one-way ANOVA was conducted to test if significant differences existed
among the different experiment types. Based on a p-value of 0.0266 from the results of
the ANOVA it was concluded that significant differences exist for the Cox-2 gene
expression. Thus, the null hypothesis was rejected. Further, a Tukey’s post-hoc analysis
was performed to identify significant differences between different sample types. As can
be seen from Table 5.3, the uncoated (bare) sample and PCL polymer coating show
statistically significant higher gene expression as compared the cells (low control). Also,
PCL polymer exhibited statistically significant difference as compared to PEUU polymer.
Table 5.3 Tukey's post hoc analysis for Cox-2 gene expression

From the results of the PCR analysis it was determined that the cell response
exhibited through inflammation was due to the increase in magnesium ion content.
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It

was also determined that the differences between polymer materials when compared
amongst each other were insignificant and showed no negative influences on cell health.
Lastly, when the desire is to decrease the rate of corrosion for magnesium alloys, PCL
was not the best candidate as its performance was similar to the uncoated samples. The
PLGA and PEUU coatings offered better protective coatings.
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CHAPTER 6
CONCLUSIONS
6.1 Overview
The objective of this research was to apply a novel surface modification technique
namely Direct-Write Inkjet printing, to develop functional coatings for metallic
biomaterials. Inkjet printing offers several advantages such as the capability to produce
coatings on extremely complex structures, deposition onto the outer surfaces only, and
flexibility to change coating design and materials. This technique also allows for the
adjustment of coating thickness with the objective of obtaining desired release patterns.
6.2 Controlled Release Coatings
Controlled release coatings are fabricated to suit a variety of different
applications. More specifically, the controlled release of various biological agents from
biodegradable polymer coatings to treat a vast number of physiological ailments is of
particular interest. The use of the Direct Write inkjet technique as a mechanism for
developing controlled release coatings offers a variety of advantages for coating surfaces
containing biological and pharmaceutical reagents [48]. For instance, this technique uses
a data driven pressure source for deposition of material onto a given substrate, where
other fabrication techniques use electricity, which may compromise the integrity of the
biological substances [48]. Other techniques such as spin coating and dip coating are not
able to accommodate the complex structures that are usually required by surgical implant
devices. None of the deposition techniques discussed earlier offer the ability to deposit
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target specific coatings, maintain the integrity of the deposition material, and eliminate
cross-contamination of materials.
The need for a coating technique that encompasses all of the benefits mentioned
above is necessary to develop controlled release coating where spatial requirements can
be specified to develop coatings with specified porosity and degradation features. In this
research, the intent was achieve a variety of drug release profiles that could be tailored to
support the needs of a given drug delivery application. Here, the drug concentration and
layers of coating material were varied to assess coating specifications resulting in a
steady state release throughout its intended time of function. This result would be
desirable for ailments requiring extended therapeutic sessions such as neointimal
hyperplasia, using an anti proliferative such as Paclitaxel, following placement of a
cardiovascular stent device [6]. Coatings having a more profound initial burst phase were
also attempted.

These coatings would be more suitable for applications such as

antimicrobial and/or antifibrotic therapy were the majority of the reagent is required in
the initial stages of treatment to treat infection at the implant site and promote healthy
wound healing [83-84].
The coating process required that various concentrations of the synthesized
biopolymer fluids were tested to determine their “jettability”. In this research, the term
jettability was defined as being able to maintain a steady jet for a time period of at least
2-3 hours. Thus, a steady jet was achieved for non-newtonian fluids. This process was
known as the jetting optimization process. In a preliminary study jetting optimization
was attempted for PEUU at 2% w/v, 1.5% w/v, 1% w/v, and 0.5% w/v. It was concluded
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that the concentration for which a steady jet was obtained for PEUU was 0.5 % w/v. The
specific jetting parameters for this material were provided in Chapter 4.
The non-contact, data-driven deposition process showed suitability for depositing
drug-loaded polymer (Paclitaxel and PEUU) on to a titanium substrate simulating stentcoating applications. The coatings types were varied in polymer and drug concentration
and thickness to determine how manipulating the three would affect the drug release
profile. Preliminary studies revealed that drug release could be achieved for a period of
35 days, which was comparable to release periods of using other notable coating
techniques found in literature. After 5 days, the samples with thicker coatings began to
peel from the substrate and thus characterization release was not obtained after that time
period. The thinner coatings with lower drug concentrations showed a steady release
pattern.
Further studies were conducted in which the polymer concentration remained
constant (0.5% w/v) and only the drug concentration and layer thickness were varied to
determine their effect on the drug release profile as well as hemocompatibility and cell
inhibition. The titanium substrates underwent standard cleaning procedures to improve
polymer surface adhesion.
Drug release profiles were obtained for a 21-day period. A design of experiment
(DOE) was used to determine the main and interaction affects of each factor on the total
drug release as well as the percentage released during the burst release period. Higher
percentages of drug release during the burst phases were observed for the samples with
thinner coatings and vice versa. The overall drug concentrations observed at the end of
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21 days where significantly lower for samples with lower drug loading. In terms of the
coating thickness, an increased coating layer generally showed higher final
concentrations then samples coated with fewer layers. The P-values obtained from the
DOE were highly significant (p < 0.01).

It was concluded that tunable drug release

coatings could be fabricated to suit various therapeutic requirements.
The reagent chosen, Paclitaxel, has been proven to inhibit accelerated cell
proliferation in cancerous environments, thus biological testing was conducted to relate
the drug release profiles to cell inhibition. MTT assay was performed on rat smooth
muscle cells after being cultured on the surfaces of taxol-loaded polymer coatings for 1,
4, and 7 days. Cells were also cultured on TCPS material, uncoated titanium, and 10 and
20 layers of PEUU with no drug as controls. A one-way ANOVA was performed to
determine any significant differences within each of the experiment types and the
controls. Significant differences were determined for each of the experiment types as
compared to the controls.
Hemocompatibility test were also conducted to relate drug release to blood
coagulation on the functionalized surfaces. Platelet deposition onto the sample surfaces
was determined by LDH assay. The statistical significance between sample groups was
determined using One-way Analysis of Variance (ANOVA) and post-hoc Newman-Keuls
testing was performed to determine specific differences. Statistical significance between
the samples containing only PEUU (control) and both sets of samples containing 5% and
10% taxol embedded in PEUU were observed. However, although differences were
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observed when increasing drug concentration from 5% w/v to 10% w/v, the effect on
blood platelet deposition was found to be insignificant.
6.3 Polymer Coatings for Controlling the Corrosion of Mg Alloys
Biofunctional coatings are necessary to suit a variety of different medical
applications. The use of the Direct Write inkjet technique as a mechanism for enhancing
the structural integrity of a given biomaterial via biofunctional coatings, namely
magnesium and its alloys, is of growing interest. Uses for magnesium as a biomaterial
offers several advantages and can spread across a number of applications. For instance,
magnesium is essential to over 300 physiological functions within the body [85] and has
also been identified as a potential biomaterial to facilitate bone growth and repair due to
proven similarities of mechanical strength with the cortical bone [86].
Direct Write deposition can be used to fabricate coatings where spatial
requirements can be specified to develop coatings with specified porosity and
degradation features for inhibiting the corrosion of magnesium alloys. In this study, the
intent was to investigate a variety of polymer coatings having various rates of
degradation. Here, the polymer type and layers of coating material were varied to assess
coating specifications for applications in corrosion protection and controlled release of
magnesium alloys. Corrosion protection is essential to ensure that a polymer coating is
applied, which can extend the life of the surgical device until its intended function is
completed [86]. The controlled release of magnesium in the trachea can be beneficial in
relaxing airway cells when exposed to an environment causing inflammation [87].
Magnesium deficiencies have also been linked to cardiovascular disease.
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Thus,

controlled release of magnesium via controlled release coatings can offer some benefit
when applied to tracheal and cardiovascular stent devices [88].
The direct-write inkjet technique was used to develop polymer coatings that
would aid in controlling corrosion of magnesium alloys for orthopedic and vascular
applications. It was hypothesized that by manipulating droplet sizes and pitch distance as
well as polymer type and thickness, desirable corrosion rates based on a given application
could be obtained. The jetting optimization process was carried out to determine the
highest printable concentration for both PCL and PLGA. It was determined that both
polymers could be printed at 1% w/v concentration (provided in Chapter 4).

The

concentration for PEUU remained at 0.5% w/v.
In a preliminary study, the direct-write printing process was utilized to deposit
precise layers of multilayer polymeric coatings on Mg alloy surface (Mg: 90%, Zn: 8.9%,
Ca: 0.5%, rest impurities). PLGA and PCL polymers coatings displayed distinct
corrosion characteristics based on their varying degradation properties. The uncoated
(bare) Mg alloy sample showed incremental weight gain and loss due to formation and
release of Mg(OH)2 corrosion products, respectively. The coating types were classified
based on polymer type (PCL and PLGA) and pitch distance (50 µm, 100 µm). Coatings
with larger deposition pitch (100µm) had higher porosity in both polymer types. This
resulted in media infiltration and corrosion of local regions on the substrate. The
corrosion behavior of PCL-50 and PLGA-50 was analogous, though PCL-50 showed
slower corrosion rate. The PCL-100 film retained corrosion products due to better
adhesion properties with the Mg substrate. The results showed that by varying polymer
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type and printing conditions one could adjust the corrosion rate of magnesium alloys for
its intended uses. Manipulation of the step and pitch sizes allowed for added control of
coating degradation based on one of the given applications provided above.
In a further study, the pitch distance remained constant (50 µm) to achieve more
protective coatings with a third polymer type (PEUU). Immersion testing was conducted
to determine the affect of polymer type and coating thickness on the presence of
magnesium released in simulated body fluid (SBF). Uncoated samples were also tested
as a control and sample aliquots were collected over an 8-day period. Magnesium ion
content was measured using inductively coupled plasma (ICP) spectroscopy technique.
Statistical analysis was conducted to determine the main and interaction effects
amongst the treated samples.

Though there were visible trends from the data, the

differences of means amongst the coating types were not significant. A analysis was
conducted to compare each experiment type against the control (uncoated). The results
from this analysis showed that the difference in the data mean for the uncoated samples
was statistically different from the mean samples coated with 20 passes of PEUU. This
suggests that PEUU with increased coated materials would be ideal for applications such
as bone growth and repair where slower corrosion rates is required to match the rate of
bone growth.
The controlled release of magnesium in the trachea can be beneficial in relaxing
airway cells when exposed to an environment causing inflammation [87]. Cell viability
and surface interaction between NHBE (airway) cells and the magnesium alloy with
various coating types were also investigated in culture. LDH activity was assessed to
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determine the effect of magnesium exposure from different samples on cytotoxicity.
Although the results showed varying levels of LDH release for the coated samples,
cytotoxicity levels were within permissible physiological limits (i.e. < 30%) after 24
hours of exposure. ANOVA results concluded that there was a significant difference
between the mean LDH release from cells containing uncoated magnesium samples and
the cells having no magnesium exposure. The analysis also revealed that, compared to
the cells with no magnesium exposure, the cells exposed to magnesium showed increased
health during the testing period. This confirms that airway cells would benefit from the
controlled release of magnesium to promote good health within the trachea.
ICP analysis was conducted to evaluate the magnesium content present within
samples. The low control (cell only) had statistically significant lower Mg ion presence as
compared to the uncoated samples. There was also a significant difference between the
low control and the samples containing the PCL coating. Statistical differences were
found between the samples containing the PEUU coating and both the PCL and uncoated
samples.
From the results, it was determined that the PCL-coated samples produced
equivalent magnesium content in SBF when compared to uncoated. Thus, the PCL
polymer is not an ideal polymer material if the intent is to retard the corrosion process.
The magnesium content observed in the sample media from the PEUU-coated
magnesium was similar to the amount observed from the low control (cells only). PLGA
offered slightly lower protection than the PEUU. Because the PCL coating was similar to
that of the uncoated sample and PEUU was similar to the low control, significant
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differences were found between PEUU and PCL. These findings were also consistent
with the results from the immersion and LDH tests thus, validating the relationship
between magnesium exposure and cell health.
A polymerase chain reaction (PCR) analysis was performed to measure the Cox-2
gene expression in NHBE cells exposed to different sample conditions. The Cox-2 gene
expression is indicative of the inflammatory response of the cells exposed to the various
polymer-coating types. Higher Cox-2 gene expression was found in both the uncoated
and PCL polymer coated which was consistent with the findings from the previous
experiments. This suggests that after 29 hours of continuous exposure to high levels of
magnesium, percentage of LDH began to approach the level of acceptability (i.e. 30%).
The results also revealed that the PEUU and PLGA polymer coating material seemed to
be the most biocompatible, as the Cox-2 gene expression for those samples were most
similar to that of the cells alone.
In conclusion, there is sufficient evidence to state that the inflammatory response
of the cells is proportional to the increasing magnesium exposure.

If the intent is to

control the corrosion rate of magnesium alloys for a given application, PCL can be
excluded as a potential candidate for coating as it corrodes at similar rates as the
magnesium alloy with no coating. PEUU and PLGA polymers may be considered for
further testing as the showed good biocompatibility and corrosion control. Therefore, this
research establishes a foundation for determining the best candidate polymer material for
controlling the corrosion of magnesium alloys as they apply to numerous applications for
controlled degradation of biomaterials for surgical implant devices.
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6.4 Future Work
6.4.1 Controlled Release Coating
•

New polymeric materials should be incorporated as possible candidate to
achieve desired drug release profiles.

•

Biphasic and bio-triphasic drug delivery coatings should be developed to
achieve a desired therapeutic effect.

6.4.2 Polymer Coatings for Corrosion Retardation
•

Further biological testing should be conducted regarding cell response to
polymer-coated magnesium.

•

Chemical properties of a given polymer type should be adjusted to inhibit
the corrosion process, namely PLGA.

•

Biphasic and bio-triphasic drug delivery coatings should be incorporated
to enhance the surface of the magnesium substrate.
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APPENDIX A
CONTROLLED RELEASE COATINGS
Full Factorial Design for Burst Release
Factors: 2 Base Design:
2, 4
Runs: 8 Replicates:
2
Blocks: 1 Center pts (total): 0
All terms are free from aliasing.
Design Table (randomized)
Run A B
1 - +
2 + 3 + +
4 + 5 - +
6 - 7 - 8 + +

Factorial Fit: Burst Release versus %Taxol Con., No. of passes
Estimated Effects and Coefficients for Burst Release (coded units)
Term
Effect Coef SE Coef
T
P
Constant
0.60569 0.005898 102.69 0.000
%Taxol Con.
0.42379 0.21190 0.005898 35.93 0.000
No. of passes
0.13340 0.06670 0.005898 11.31 0.000
%Taxol Con.*No. of passes 0.19379 0.09690 0.005898 16.43 0.000
S = 0.0166827 R-Sq = 99.76% R-Sq(adj) = 99.59%
Analysis of Variance for Burst Release (coded units)
Source
DF Seq SS Adj SS Adj MS
F
P
Main Effects
2 0.394790 0.394790 0.197395 709.26 0.000
2-Way Interactions 1 0.075111 0.075111 0.075111 269.88 0.000
Residual Error
4 0.001113 0.001113 0.000278
Pure Error
4 0.001113 0.001113 0.000278
Total
7 0.471014
Estimated Coefficients for Burst Release using data in uncoded units
Term

Coef
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Constant
0.641970
%Taxol Con.
-0.0315170
No. of passes
-0.0447980
%Taxol Con.*No. of passes 0.00775170
Least Squares Means for Burst Release
Mean SE Mean
%Taxol Con.
5
0.3938 0.008341
10
0.8176 0.008341
No. of passes
10
0.5390 0.008341
20
0.6724 0.008341
%Taxol Con.*No. of passes
5 10
0.4240 0.011796
10 10
0.6540 0.011796
5 20
0.3636 0.011796
10 20
0.9812 0.011796
Alias Structure
I
%Taxol Con.
No. of passes
%Taxol Con.*No. of passes

Total Release DOE
Factorial Fit: Total Release versus %Taxol Con., No. of passes
Estimated Effects and Coefficients for Total Release (coded units)
Term
Effect Coef SE Coef
T
P
Constant
59.14 0.3650 162.04 0.000
%Taxol Con.
49.72 24.86 0.3650 68.11 0.000
No. of passes
33.81 16.91 0.3650 46.32 0.000
%Taxol Con.*No. of passes 20.01 10.00 0.3650 27.41 0.000
S = 1.03233 R-Sq = 99.95% R-Sq(adj) = 99.91%
Analysis of Variance for Total Release (coded units)
Source
DF Seq SS Adj SS Adj MS
F
P
Main Effects
2 7230.07 7230.07 3615.04 3392.17 0.000
2-Way Interactions 1 800.40 800.40 800.40 751.06 0.000
Residual Error
4 4.26 4.26 1.07
Pure Error
4 4.26 4.26 1.07
Total
7 8034.73
Estimated Coefficients for Total Release using data in uncoded units
Term

Coef
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Constant
23.8700
%Taxol Con.
-2.06000
No. of passes
-2.62000
%Taxol Con.*No. of passes 0.800200
Least Squares Means for Total Release
Mean SE Mean
%Taxol Con.
5
34.29 0.5162
10
84.00 0.5162
No. of passes
10
42.24 0.5162
20
76.05 0.5162
%Taxol Con.*No. of passes
5 10
27.38 0.7300
10 10
57.09 0.7300
5 20
41.19 0.7300
10 20
110.91 0.7300
Alias Structure
I
%Taxol Con.
No. of passes
%Taxol Con.*No. of passes
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APPENDIX B
POLYMER COATINGS FOR COROSION RETARDATION: A PILOT STUDY
Overview
Appendix B details the preliminary experiment procedure for cell culture and
surface-cell interactions experiments. The experimental results and statistical analysis
from this preliminary test are also presented here.
Cell Culture Procedure
Normal Human Bronchial Epithelial (NHBE) cells were cultured in complete
media, which consisted of a 50:50 mixture of BEBM/DMEM supplemented with
antibiotics and growth factors. The cells were rapidly thawed from liquid nitrogen in a
37oC water bath and seeded in 6-well culture dishes fitted with rat tail collagen-coated
polycarbonate membrane Transwell® inserts (0.4 µm pore). Complete media (500 mL)
was prepared by combining 250 mL of BEBM and 250 mL of DMEM into a flask with
SingleQuot® components. The cells were fed apically and basolaterally every other day
until they reached 100% confluency (at approximately 7 days). At that point, an air
liquid interphase (ALI) was established by removing medium from the apical chamber
and cells were fed basolaterally everyday for 14 days to allow full differentiation of the
airway epithelial phenotype. . The cells were cultured at 37°Celcius in humidified air
and 5% CO2.
Cell – Surface Interface Testing Procedure
The 10X10 mm Mg samples (n=3 per coating) were coated with 20 layers of
polymer and sterilized under a laminar flow hood with a UV sterilization bulb for 15
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minutes on each side. Due to apparent differences in cells across the wells, the wells,
which looked the healthiest, were chosen for the experiment. Each of the samples were
assigned a well number were they were placed face down such that the coated
magnesium surface was in direct contact with the epithelial cell layer. The wells were
labeled as the low control, thus they were cells, which were untreated. Initial media
samples were collected from each well at time zero and stored at -20oC until need for
lactate dehydrogenase (LDH) and or elemental analysis via inductively coupled plasma
mass spectrometry (ICP-MS).

Fresh medium was placed in the lower chamber of each

well and the plates were placed in incubation at 37°C and 5% CO2.
Balolateral medium samples were collected again at 1 hour, 4, hours, 6 hours, 24
hours, and 48 hours. During the sample collection period, 1.5 mL of the sample media
was collected from each of the wells and placed into a small tube. The tubes were
labeled and frozen at -20°C. Any remaining media was aspirated from the cell well and
two mL of fresh media was reapplied to the lower chamber. During this period, selected
wells were imaged by phase contrast microscopy using an Evos xl inverted microscope
(AMG). After the final sample collection, the wells containing the untreated cells were
lysed such that all LDH activity would be released. These samples were then labeled as
the high control and used for LDH analysis.
LDH Assay
Following exposure to coated Mg samples, reactions were terminated by
removing materials from the apical surface, collection of basolateral culture medium and
plates were wrapped in foil and stored at -80o C until needed for gene expression analysis.
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The Roche cytotoxicity detection kit was used to determine LDH release by the cells at
the indicated time points. The low control consisted of the untreated cells (n=3) and the
high control consisted of the lysed cells, which provided information about the maximum
amount of released LDH activity in the cells. The assay was performed according to
manufacture’s recommendation and samples (in triplicate) were transferred into a 96-well
plate according to the template found below.
Table A.1 96-well template for preliminary LDH data collection

Absorbance measurements were taken for each time point at 492 nm on a
VersaMAX microplate reader (Molecular Devices).

To determine the percentage

cytotoxicity, the average of the triplicates were obtained and the cytotoxicity percentage
was calculated using equation. Where, exp. is the experimental value obtained from the
absorbance readings, low control is the absorbance value obtained from cells with no
magnesium exposure, and high control is the absorbance value obtained from samples
containing the maximum LDH activity.

Experimental Design
The purpose of this experiment was to gauge the effects of polymer coating
material on the percentage of LDH activity from the cultured cells. The various
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conditions identified for comparison were untreated magnesium alloys, samples coated
with PCL, PLGA, and PEUU. A low control that consisted of cultured cells with no
magnesium exposure.

Having this low control would allow us to compare the

magnesium containing samples to the natural cell death process. A one-way analysis of
variance was chosen to determine the statistical differences between the means of the
various experiment groups.
The question was posed, “Can direct-write inkjet printing be used as a mechanism
for depositing uniformly distributed protective thin films?” Furthermore, “Can these thin
films aid in retardation of the corrodible AZ31 magnesium alloy in physiological
solutions?” More specifically, we seek to answer the following questions:
1. Does polymer type and coating thickness have a significant effect on the rate of
metal ion release? (Phase 1)
2. Does polymer coating type have a significant effect on the percentage of LDH
activity from Human Bronchial Epithelial Cells? (Phase 2)
Results
Preliminary cell culture testing was conducted to determine the effects of polymer
coating type on the percentage of LDH activity and magnesium presence in sample media
at various time points. LDH activity was collected over a course of a 48 hour period at t =
0, 1, 4, 6, 24 and 48 hours. The sample data collected at time zero represents two distinct
events. The first is that this sample was collected at the end of a 24-hour feeding during
which some LDH activity had already occurred. This is apparent in the graph shown
below which depicts a sample reading that shows significantly higher LDH activity when
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compared to subsequent readings. Also, at time zero fresh media was added to each of
the sample wells to initiate the new testing period. Thus, it is taken that each time point
represents the end of a sample collection period.
The samples collected at each time period were evaluated as percentages of the
high control, that is, the total amount of LDH that could be released from the cells.
Given that the samples collected at time zero contained 24 hours worth of LDH activity
before magnesium exposure, this provided some indication of the cell health before the
experiment was started.

The sample data collected at time zero indicates that the cell

health of the wells that were chosen as the low control was significantly lower than the
wells assigned to the other experiment groups due to a high percentage of LDH release.
Sample media collected between t = 1 and t = 6 hours showed very little LDH
release occurred and that activity was fairly consistent between the experiment groups.
Between t = 6 and t = 24 hours a slight jump in percentage LDH activity is realized with
PEUU coated samples having the highest activity and uncoated samples showing the
least. Finally, at t = 48 hours the data shows a great increase in all of the experiment
groups, however it remains that the PEUU show the highest release percentage where the
uncoated samples continue to show the least. The results indicated that the cells are able
to maintain good health as they are exposed to the magnesium. However the cells seem
to react more to the polymer coatings, specifically, PEUU.
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Figure A.1 Depiction of fluctuating LDH for all time points of preliminary study
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(a)

(b)
Figure A.2 (a) Depiction of trends in LDH activity over 24 hours (b) increasing LDH
activity over 24 hours for preliminary data set
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A one-way analysis of variance (ANOVA) was conducted to determine if there
are significant differences between the means of the experiment groups. The results
showed that significant differences do exist between at least two of the sample types (p <
0.05). Therefore, the null hypothesis stating that there are no differences between the
means was rejected and further analysis was required. Tukey’s analysis was conducted to
determine specific differences between groups.

Here results showed that statistical

differences occurred between the low control (cells only) and the uncoated samples. The
differences amongst all other sample types were shown to be insignificant.

Figure A.3 Depiction of differences in LDH for preliminary data set
Samples from each experiment group were also collected for inductively coupled
plasma (ICP) analysis. The ICP analysis was to determine whether or not the various
treatment types affected magnesium presences within the collected samples. The data
shows higher magnesium presences from PCL-coated samples and lower magnesium
presence for PEUU-coated samples. A one-way ANOVA was performed on the data,
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which revealed that the differences in means for magnesium presences were not
significant thus; the results here were likely due to chance and possibly variations in the
sample types. Overall, it seemed that cells may be reacting to the polymer type as oppose
to magnesium exposure.

Figure A.4 Magnesium presence in LDH samples for preliminary data set

Figure A.5 Depiction of mean differences in mg content for preliminary data
Conclusions
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Normal Human Bronchial Epithelial cells were culture in Air-Liquid Interface.
Magnesium samples set in epoxy resin material were coated using direct-write
techniques. Cell wells were selected bases on apparent cell health at the start of the
experiment and randomly assigned to an experiment group. The samples were placed for
surface interaction between the cells and polymer coated magnesium surfaces in which
the samples were tested for percentage of LDH activity and magnesium presence in the
sample fluid.
Statistical analysis (ANOVA) was conducted on the results for a 48-hour period,
which determined that there were no significant differences in the polymer coating types
on the percentage of LDH activity. However the difference in means between the cells
and the uncoated samples was significant indication a positive reaction to the magnesium
from the uncoated samples. It is also evident from the results of the test that declining
cell health could be a response to the biocompatibility of the polymer types rather than
increased magnesium exposure.
In conclusion, this test should be conducted again with cells having similar health
at the start of the experiment. Also smaller samples sizes should be used to eliminate the
possibility of weight contributing to accelerated cell stress.
Statistical Analysis for Preliminary Experiments
LDH shows statistical significance for NOV
One-way ANOVA: Nov LDH
Source DF
SS MS F
P
NOV_L24 4 869.7 217.4 4.31 0.028
Error 10 504.9 50.5
Total 14 1374.6
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S = 7.106 R-Sq = 63.27% R-Sq(adj) = 48.58%
Individual 95% CIs For Mean Based on
Pooled StDev
Level N Mean StDev -+---------+---------+---------+-------Bare 3 27.916 1.765 (--------*--------)
Cells 3 47.403 8.556
(--------*---------)
PCL 3 29.004 7.374 (--------*--------)
PEUU 3 38.709 10.630
(--------*--------)
PLGA 3 28.822 2.958 (--------*--------)
-+---------+---------+---------+-------20
30
40
50
Pooled StDev = 7.106
Tukey 95% Simultaneous Confidence Intervals
All Pairwise Comparisons among Levels of NOV_L24
Individual confidence level = 99.18%
NOV_L24 = Bare subtracted from:
NOV_L24 Lower Center Upper ---------+---------+---------+---------+
Cells
0.411 19.487 38.563
(---------*--------)
PCL
-17.988 1.088 20.164
(---------*--------)
PEUU
-8.283 10.793 29.870
(--------*---------)
PLGA -18.169 0.907 19.983
(--------*---------)
---------+---------+---------+---------+
-20
0
20
40
NOV_L24 = Cells subtracted from:
NOV_L24 Lower Center Upper ---------+---------+---------+---------+
PCL
-37.475 -18.399 0.677 (---------*--------)
PEUU -27.770 -8.694 10.382
(---------*--------)
PLGA -37.657 -18.581 0.495 (---------*--------)
---------+---------+---------+---------+
-20
0
20
40
NOV_L24 = PCL subtracted from:
NOV_L24 Lower Center Upper ---------+---------+---------+---------+
PEUU
-9.371 9.705 28.781
(---------*--------)
PLGA -19.258 -0.182 18.894
(---------*--------)
---------+---------+---------+---------+
-20
0
20
40
NOV_L24 = PEUU subtracted from:
NOV_L24 Lower Center Upper ---------+---------+---------+---------+
PLGA -28.963 -9.887 9.189
(--------*---------)
---------+---------+---------+---------+
-20
0
20
40
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NOV ICP Data does not show statistical significance
One-way ANOVA: Nov ICP NHBE
Source DF
SS
MS F
P
Nov18_T24 4 0.0000000 0.0000000 1.12 0.400
Error
10 0.0000000 0.0000000
Total
14 0.0000000
S = 0.00005312 R-Sq = 30.93% R-Sq(adj) = 3.30%

Level N
Mean
StDev
Bare 3 0.00018672 0.00000492
Cells 3 0.00014152 0.00000460
PCL 3 0.00023239 0.00009136
PEUU 3 0.00017941 0.00005646
PLGA 3 0.00017791 0.00005027
Individual 95% CIs For Mean Based on Pooled StDev
Level --------+---------+---------+---------+Bare
(----------*-----------)
Cells (-----------*----------)
PCL
(-----------*----------)
PEUU
(----------*----------)
PLGA
(-----------*----------)
--------+---------+---------+---------+0.000120 0.000180 0.000240 0.000300
Pooled StDev = 0.00005312
Tukey 95% Simultaneous Confidence Intervals
All Pairwise Comparisons among Levels of Nov18_T24
Individual confidence level = 99.18%
Nov18_T24 = Bare subtracted from:
Nov18_T24
Lower
Center
Upper
Cells
-0.00018780 -0.00004520 0.00009741
PCL
-0.00009693 0.00004567 0.00018828
PEUU
-0.00014991 -0.00000730 0.00013530
PLGA
-0.00015141 -0.00000880 0.00013380
Nov18_T24 ---------+---------+---------+---------+
Cells
(-----------*-----------)
PCL
(-----------*-----------)
PEUU
(----------*-----------)
PLGA
(-----------*-----------)
---------+---------+---------+---------+
-0.00012 0.00000 0.00012 0.00024
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Nov18_T24 = Cells subtracted from:
Nov18_T24
Lower
Center
Upper
PCL
-0.00005173 0.00009087 0.00023348
PEUU
-0.00010471 0.00003789 0.00018050
PLGA
-0.00010621 0.00003640 0.00017900
Nov18_T24 ---------+---------+---------+---------+
PCL
(-----------*----------)
PEUU
(-----------*-----------)
PLGA
(-----------*-----------)
---------+---------+---------+---------+
-0.00012 0.00000 0.00012 0.00024
Nov18_T24 = PCL subtracted from:
Nov18_T24
Lower
Center
Upper
PEUU
-0.00019558 -0.00005298 0.00008963
PLGA
-0.00019708 -0.00005448 0.00008813
Nov18_T24 ---------+---------+---------+---------+
PEUU
(-----------*----------)
PLGA
(----------*-----------)
---------+---------+---------+---------+
-0.00012 0.00000 0.00012 0.00024
Nov18_T24 = PEUU subtracted from:
Nov18_T24
Lower
Center
Upper
PLGA
-0.00014410 -0.00000150 0.00014111
Nov18_T24 ---------+---------+---------+---------+
PLGA
(-----------*-----------)
---------+---------+---------+---------+
-0.00012 0.00000 0.00012 0.00024
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APPENDIX C
Statistical Output for Magnesium Ion Content from Immersion Testing

DOE ICP Mg –Immersion Test
Multilevel Factorial Design
Factors:
2 Replicates: 2
Base runs: 6 Total runs: 12
Base blocks: 1 Total blocks: 1
Number of levels: 3, 2
Design Table (randomized)
Run
1
2
3
4
5
6
7
8
9
10
11
12

Blk A B
1 3 1
1 3 2
1 2 1
1 1 1
1 2 1
1 3 2
1 1 2
1 3 1
1 1 2
1 2 2
1 2 2
1 1 1

General Linear Model: Mg-Immer versus Polymer Type, No. of Layers
Factor
Type Levels Values
Polymer Type fixed
3 PCL, PLGA, PEUU
No. of Layers fixed
2 10, 20
Analysis of Variance for Mg-Immer, using Adjusted SS for Tests
Source
DF Seq SS Adj SS Adj MS F
P
Polymer Type
2 0.0000114 0.0000114 0.0000057 2.15 0.198
No. of Layers
1 0.0000002 0.0000002 0.0000002 0.09 0.770
Polymer Type*No. of Layers 2 0.0000197 0.0000197 0.0000099 3.74 0.088
Error
6 0.0000159 0.0000159 0.0000026
Total
11 0.0000472
S = 0.00162534 R-Sq = 66.41% R-Sq(adj) = 38.43%
Term
Constant

Coef SE Coef
T
P
0.002990 0.000469 6.37 0.001
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Polymer Type
PCL
0.001277 0.000664 1.92 0.103
PLGA
-0.000195 0.000664 -0.29 0.778
No. of Layer
10
0.000144 0.000469 0.31 0.770
Polymer Type*No. of Layer
PCL
10
-0.001804 0.000664 -2.72 0.035
PLGA
10
0.001062 0.000664 1.60 0.161
Least Squares Means for Mg-Immer
Polymer Type
Mean SE Mean
PCL
0.004267 0.000813
PLGA
0.002794 0.000813
PEUU
0.001908 0.000813
No. of Layer
10
0.003133 0.000664
20
0.002846 0.000664
Polymer Type*No. of Layer
PCL
10
0.002606 0.001149
PCL
20
0.005927 0.001149
PLGA
10
0.003999 0.001149
PLGA
20
0.001589 0.001149
PEUU
10
0.002794 0.001149
PEUU
20
0.001021 0.001149

ANOVA ICP Mg – Immersion Test
One-way ANOVA: Mg-Imm versus Immer
Source DF
SS
MS
F
Immer 6 0.0000714 0.0000119 4.45 0.036
Error
7 0.0000187 0.0000027
Total 13 0.0000901

P

S = 0.001635 R-Sq = 79.23% R-Sq(adj) = 61.42%
Individual 95% CIs For Mean Based on
Pooled StDev
Level N Mean StDev -----+---------+---------+---------+---Bare 2 0.007821 0.001690
(------*-------)
PCL10 2 0.002606 0.000318
(------*-------)
PCL20 2 0.005927 0.003085
(-------*-------)
PEUU10 2 0.002794 0.000011
(-------*-------)
PEUU20 2 0.001021 0.000213 (-------*-------)
PLGA10 2 0.003999 0.002483
(------*-------)
PLGA20 2 0.001589 0.000157 (-------*------)
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-----+---------+---------+---------+---0.0000 0.0035 0.0070 0.0105
Pooled StDev = 0.001635
Tukey 95% Simultaneous Confidence Intervals
All Pairwise Comparisons among Levels of Immer
Individual confidence level = 99.46%
Immer = Bare subtracted from:
Immer
Lower Center Upper
PCL10 -0.011699 -0.005214 0.001271
PCL20 -0.008378 -0.001893 0.004592
PEUU10 -0.011511 -0.005026 0.001459
PEUU20 -0.013284 -0.006799 -0.000314
PLGA10 -0.010306 -0.003821 0.002664
PLGA20 -0.012717 -0.006232 0.000253
Immer ---------+---------+---------+---------+
PCL10 (---------*--------)
PCL20
(--------*---------)
PEUU10 (--------*--------)
PEUU20 (--------*---------)
PLGA10 (---------*--------)
PLGA20 (--------*--------)
---------+---------+---------+---------+
-0.0070 0.0000 0.0070 0.0140
Immer = PCL10 subtracted from:
Immer
Lower Center Upper
PCL20 -0.003164 0.003321 0.009806
PEUU10 -0.006297 0.000188 0.006673
PEUU20 -0.008070 -0.001585 0.004900
PLGA10 -0.005092 0.001393 0.007878
PLGA20 -0.007503 -0.001017 0.005468
Immer ---------+---------+---------+---------+
PCL20
(---------*--------)
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PEUU10
(--------*---------)
PEUU20
(---------*--------)
PLGA10
(--------*--------)
PLGA20
(---------*--------)
---------+---------+---------+---------+
-0.0070 0.0000 0.0070 0.0140
Immer = PCL20 subtracted from:
Immer
PEUU10
PEUU20
PLGA10
PLGA20

Lower Center Upper
-0.009618 -0.003133 0.003352
-0.011391 -0.004906 0.001579
-0.008413 -0.001928 0.004557
-0.010824 -0.004339 0.002146

Immer ---------+---------+---------+---------+
PEUU10
(---------*--------)
PEUU20 (--------*--------)
PLGA10
(--------*---------)
PLGA20
(--------*--------)
---------+---------+---------+---------+
-0.0070 0.0000 0.0070 0.0140
Immer = PEUU10 subtracted from:
Immer
PEUU20
PLGA10
PLGA20

Lower Center Upper
-0.008258 -0.001773 0.004712
-0.005280 0.001205 0.007690
-0.007690 -0.001205 0.005280

Immer ---------+---------+---------+---------+
PEUU20
(--------*---------)
PLGA10
(---------*--------)
PLGA20
(--------*---------)
---------+---------+---------+---------+
-0.0070 0.0000 0.0070 0.0140
Immer = PEUU20 subtracted from:
Immer
Lower Center Upper
PLGA10 -0.003507 0.002978 0.009463
181

PLGA20 -0.005917 0.000568 0.007053
Immer ---------+---------+---------+---------+
PLGA10
(--------*---------)
PLGA20
(--------*--------)
---------+---------+---------+---------+
-0.0070 0.0000 0.0070 0.0140
Immer = PLGA10 subtracted from:
Immer
Lower Center Upper
PLGA20 -0.008896 -0.002411 0.004074
Immer ---------+---------+---------+---------+
PLGA20
(---------*--------)
---------+---------+---------+---------+
-0.0070 0.0000 0.0070 0.0140
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APPENDIX D
STATISTICAL OUTPUT FOR FINAL LDH ACTIVITY AND MG CONTENT IN
CULTURE MEDIA
LDH shows statistical significance for DEC
One-way ANOVA: LDH-T24_DEC
Source DF
SS MS F
P
DEC_L24 4 848.0 212.0 3.75 0.041
Error 10 564.7 56.5
Total 14 1412.6
S = 7.514 R-Sq = 60.03% R-Sq(adj) = 44.04%
Individual 95% CIs For Mean Based on
Pooled StDev
Level N Mean StDev -----+---------+---------+---------+---Bare 3 28.080 4.594 (-------*-------)
Cells 3 49.908 15.981
(-------*-------)
PCL 3 32.357 1.779
(-------*-------)
PEUU 3 37.302 0.449
(-------*-------)
PLGA 3 32.604 1.575
(-------*-------)
-----+---------+---------+---------+---24
36
48
60
Pooled StDev = 7.514
Tukey 95% Simultaneous Confidence Intervals
All Pairwise Comparisons among Levels of DEC_L24
Individual confidence level = 99.18%
DEC_L24 = Bare subtracted from:
DEC_L24 Lower Center Upper ---------+---------+---------+---------+
Cells
1.655 21.829 42.002
(---------*---------)
PCL
-15.896 4.277 24.451
(---------*---------)
PEUU -10.951 9.222 29.396
(---------*---------)
PLGA -15.650 4.524 24.698
(---------*---------)
---------+---------+---------+---------+
-20
0
20
40
DEC_L24 = Cells subtracted from:
DEC_L24 Lower Center Upper ---------+---------+---------+---------+
PCL
-37.725 -17.551 2.622 (---------*---------)
PEUU -32.780 -12.606 7.568 (---------*---------)
PLGA -37.478 -17.305 2.869 (---------*---------)
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---------+---------+---------+---------+
-20
0
20
40
DEC_L24 = PCL subtracted from:
DEC_L24 Lower Center Upper ---------+---------+---------+---------+
PEUU -15.229 4.945 25.119
(---------*----------)
PLGA -19.927 0.247 20.420
(---------*---------)
---------+---------+---------+---------+
-20
0
20
40
DEC_L24 = PEUU subtracted from:
DEC_L24 Lower Center Upper ---------+---------+---------+---------+
PLGA -24.872 -4.698 15.475
(---------*---------)
---------+---------+---------+---------+
-20
0
20
40

DEC ICP Data shows statistical significance
One-way ANOVA: Dec Mg ICP for NHBE
Source DF
SS
MS F
P
Dec16_T24 4 0.0000000 0.0000000 7.56 0.005
Error
10 0.0000000 0.0000000
Total
14 0.0000000
S = 0.000006802 R-Sq = 75.16% R-Sq(adj) = 65.22%
Individual 95% CIs For Mean Based on
Pooled StDev
Level N
Mean
StDev ----+---------+---------+---------+----Bare 3 0.00016682 0.00000595
(--------*--------)
Cells 3 0.00014512 0.00000765 (--------*--------)
PCL 3 0.00016616 0.00000375
(--------*--------)
PEUU 3 0.00014572 0.00000655 (--------*-------)
PLGA 3 0.00015067 0.00000897
(--------*-------)
----+---------+---------+---------+----0.000140 0.000150 0.000160 0.000170
Pooled StDev = 0.00000680
Tukey 95% Simultaneous Confidence Intervals
All Pairwise Comparisons among Levels of Dec16_T24
Individual confidence level = 99.18%
Dec16_T24 = Bare subtracted from:
Dec16_T24
Lower
Center
Upper
Cells
-3.99556E-05 -2.16933E-05 -3.43106E-06
PCL
-1.89136E-05 -6.51333E-07 0.000017611
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PEUU
PLGA

-3.93596E-05 -2.10973E-05 -2.83506E-06
-3.44056E-05 -1.61433E-05 0.000002119

Dec16_T24 +---------+---------+---------+--------Cells
(--------*--------)
PCL
(--------*--------)
PEUU
(--------*---------)
PLGA
(--------*--------)
+---------+---------+---------+---------4.0E-05 -2.0E-05 0.000000 0.000020
Dec16_T24 = Cells subtracted from:
Dec16_T24
Lower
Center
Upper
PCL
0.000002780 0.000021042 0.000039304
PEUU
-1.76663E-05 0.000000596 0.000018858
PLGA
-1.27123E-05 0.000005550 0.000023812
Dec16_T24 +---------+---------+---------+--------PCL
(---------*--------)
PEUU
(--------*--------)
PLGA
(--------*--------)
+---------+---------+---------+---------4.0E-05 -2.0E-05 0.000000 0.000020
Dec16_T24 = PCL subtracted from:
Dec16_T24
Lower
Center
Upper
PEUU
-3.87083E-05 -2.04460E-05 -2.18373E-06
PLGA
-3.37543E-05 -1.54920E-05 0.000002770
Dec16_T24 +---------+---------+---------+--------PEUU
(--------*--------)
PLGA
(--------*--------)
+---------+---------+---------+---------4.0E-05 -2.0E-05 0.000000 0.000020
Dec16_T24 = PEUU subtracted from:
Dec16_T24
Lower
Center
Upper
PLGA
-1.33083E-05 0.000004954 0.000023216
Dec16_T24 +---------+---------+---------+--------PLGA
(--------*---------)
+---------+---------+---------+---------4.0E-05 -2.0E-05 0.000000 0.000020
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